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 Parkinson’s disease (PD) is a chronic, progressive movement disorder that affects millions of 
patients and their families worldwide. Treatment options address some of the symptoms but do 
not affect the progression of the disease. Central to the motor symptoms of PD are due, in part, to 
the slow, progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) 
and the consequent depletion of dopaminergic neurotransmission in the striatum. As these cells 
die, they accumulate toxic levels of various substances, such as the aggregation-prone protein 
alpha-synuclein (a-syn, SNCA) and iron. It is known that expression of SNCA is aberrantly high 
in SNc dopaminergic neurons in the PD brain, but the transcriptional mechanisms that participate 
in this dysregulation are poorly understood. Recently, GATA2, a transcription factor known for 
its critical role in hematopoiesis, was shown to regulate SNCA positively and directly in vitro; 
however, it is unknown whether this mode of regulation occurs in vivo and is thereby relevant to 
PD. In this dissertation project, we assessed the relevance of GATA2 in PD by testing two 
hypotheses in a mammalian model: 1) GATA2 positively regulates SNCA in vivo in SNc 
neurons, and 2) silencing GATA2 expression in SNc neurons confers protection against the 
parkinsonian neurotoxin, rotenone. To test these hypotheses, it was necessary first to validate rat 
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as a suitable model for investigating GATA2 function in adult brain and to develop reagents for 
silencing GATA2 expression in vivo. Using a viral-mediated gene silencing approach, we found 
that GATA2 positively regulates SNCA in SNc dopaminergic neurons in adult rat. However, 
silencing GATA2 was not protective against rotenone treatment in the rat model of PD. Our 
findings are significant in that they provide the first in vivo demonstration of a transcription 
factor that regulates SNCA, a gene of central importance to PD pathogenesis. Although our data 
suggest that GATA2 is not a useful therapeutic target for PD, our findings shed some light on the 
role of GATA2 in adult SNc dopaminergic neurons, thus contributing to our understanding of 
GATA transcription factor biology in the adult brain. 
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1.0  GENERAL INTRODUCTION 
Portions of this General Introduction were previously published in the following article: 
Horowitz, M.P. and Greenamyre, J.T. “Gene-environment interactions in Parkinson’s disease: 
The Importance of Animal Modeling.” Clinical Pharmacology and Therapeutics. 2010 Oct; 
88(4): 467-74 [PMID: 20811350] 
1.1 PARKINSON’S DISEASE 
1.1.1 Disease Burden 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease (Thomas, 2009), and is a devastating, chronic illness for patients and their 
families. Advanced age is the most significant risk factor for developing PD. While overall PD 
prevalence is 100-200 per 100,000, it is estimated that 1.5-2% of the population over 65 years 
old is afflicted (de Rijk et al., 2000; 1997; Lang & Lozano, 1998a; 1998b). This corresponds to 
about 6 million PD patients worldwide, 1.5 million of whom reside in the United States (Thomas 
& Beal, 2007). These numbers are expected to increase in the next 20 years as the median age in 
the western populations rises. 
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PD affects all ethnic and racial groups, and is found throughout the world where life 
expectancy is sufficiently long for onset to occur (de Rijk et al., 1997; 2000; Lang & Lozano, 
1998a; 1998b; Nutt & Wooten, 2005; Thomas, 2009). Men are at ~1.5 times higher risk for 
developing PD than women in most populations, which has been attributed to either increased 
occupational risk among men and/or risk-reducing biological factors in women (Elbaz & 
Tranchant, 2007; Elbaz et al., 2002). Because current therapies do not modify disease 
progression, patients typically live in declining health for 15 years after diagnosis (Lees, Hardy, 
& Revesz, 2009), and they frequently develop dementia, requiring institutionalization, and 
succumb to early death, most often from pneumonia (Elbaz & Tranchant, 2007; Lees et al., 
2009). Given its chronic and invariably progressive nature, PD carries a significant burden for 
patients, their families, and the larger community. 
1.1.2 Clinical Features 
PD typically presents late in life – the median age of onset is 60 years old – with cardinal motor 
features, which include bradykinesia, rigidity, and tremor at rest (Savitt, Dawson, & Dawson, 
2006). These motor features usually begin unilaterally, but progressively worsen and become 
bilateral over the course of disease. Postural instability (with consequent falls), as well as 
swallowing difficulties related to bulbar dysfunction, can become prominent and severely 
debilitating motor complications. 
Although PD is considered to be a movement disorder based on its common presenting 
motor symptoms, many other central and peripheral nervous system domains are affected, and 
there is often significant autonomic dysfunction preceding diagnosis and occurring 
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concomitantly with motor symptoms (Chaudhuri & Schapira, 2009; Dubow, 2007; Lees et al., 
2009; van Rooden et al., 2011). Common non-motor symptoms in PD include: cognitive 
impairment or dementia, depression, hallucinations, REM behavioral sleep disorder, fatigue, 
urinary urge incontinence, constipation, impotence, orthostatic hypotension, and anosmia (Lees 
et al., 2009). These symptoms represent a significant source of disability for patients and their 
care-providers since they typically do not respond to standard PD therapies. 
PD is clinically heterogeneous in its presenting signs and symptoms, as well as the 
severity of its course, leading to the view that PD is in fact numerous distinct disease entities 
with a similar phenotype (van Rooden et al., 2011). As discussed below, the genetics of PD are 
consistent with this view. Studies have been undertaken to categorize PD sub-types based on 
motor and non-motor signs and symptoms. One recent article described four “clusters” of PD 
cases, which differ based on their non-dopaminergic features and the prevalence of motor 
complications during disease course (van Rooden et al., 2011). The goal of identifying clinical 
PD subtypes is to determine prognosis more accurately, to refine inclusion and exclusion criteria 
in clinical trials so that they have a better likelihood of success, and eventually to tailor the 
therapeutic approach more effectively. 
1.1.3 Etiology & Neuropathology 
In part, the motor symptoms of PD arise from progressive degeneration of neuromelanin-
containing, dopaminergic neurons in the substantia nigra pars compacta (SNc) and a resultant 
depletion of dopamine in the striatum, where their axons terminate. The demise of these neurons 
is insidious and motor signs do not appear until 50-70% of these cells have died (Lesage & 
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Brice, 2009). However, meticulous pathological analysis performed by Braak suggests that the 
earliest signs of PD pathology (i.e. Lewy bodies) are found outside of the SNc – in ganglia 
within the digestive tract and in the olfactory bulb – and only later progress to SNc and cortex 
(Braak et al., 2003). The finding of extra-nigral pathology may explain some non-motor features 
of PD, however the degree to which staging of Lewy pathology reflects severity of symptoms 
remains a matter of debate (Jellinger, 2009). 
What starts the process of neuronal dysfunction and death in PD is unclear. The vast 
majority of PD cases (~90%) are currently believed to be sporadic (idiopathic), meaning that 
they lack a clearly defined basis. Most cases of PD are thought to arise from a multifactorial 
interaction of environmental exposures, genetic predisposition, and aging (Horowitz & 
Greenamyre, 2010a). This means that there is not a single etiologic cause of PD. However, these 
factors appear to converge on a limited set of subcellular organelles and mechanisms 
(Greenamyre & Hastings, 2004). A minority of PD cases can be ascribed to mutations in single 
genes that have been convincingly demonstrated to be pathogenic (monogenic PD).  
Characterization of these causative genes has begun to lead to important insights into disease 
mechanisms. 
1.1.3.1 Monogenic Forms of PD 
The identification of monogenic forms of PD has led to major advances in our understanding of 
PD pathophysiology.  To date, 16 loci (PARK1-16) have been associated with PD (Lesage & 
Brice, 2009). Of these, mutations in 5 genes have been confirmed to cause parkinsonian 
syndromes that resemble PD: the dominantly inherited alpha-synuclein (SNCA) and LRRK2, and 
the recessively inherited parkin, PINK1, and DJ-1.  The remaining 11 loci require further 
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investigation to determine precisely the extent of their contribution to PD.  Much of what is 
known about PD pathogenesis has come from work investigating monogenic forms of PD in 
vitro and in vivo.  However, it should be noted that genetic mutations may give rise to clinical 
parkinsonism that does not necessarily involve the same pathogenic events as sporadic PD. In 
this context, it is prudent to exercise caution when extrapolating from monogenic cases of PD to 
pathogenic mechanisms in sporadic PD. 
Alpha-synuclein (SNCA) 
The first monogenic form of PD was discovered in families with autosomal dominant 
transmission of PD and missense mutations in the alpha-synuclein gene (SNCA) 
(Polymeropoulos et al., 1997). SNCA contains 7 exons and encodes a 140-amino acid protein (a-
syn) that localizes mostly to pre-synaptic terminals (Breydo, Wu, & Uversky, 2012). Though the 
physiologic function of a-syn is incompletely understood, it appears to function in vesicle 
recycling via interacting with membranes (Cheng, Vivacqua, & Yu, 2011). Its natively unfolded 
structure renders the protein prone to aggregation under various pathophysiological conditions, 
including the three PD-related mutations (Breydo et al., 2012). Examination of the pathological 
hallmark of PD – the Lewy body – revealed that they contain abundant a-syn (Spillantini et al., 
1997). This finding placed a-syn at the center of both familial and sporadic PD pathogenesis. 
Indeed, other PD-relevant factors were subsequently found to enhance a-syn aggregation and 
toxicity, including: oxidative modification; phosphorylation at serine 129; C-terminal 
truncations; interactions with metals, certain proteins or lipids; pesticides; and increased steady-
state levels of a-syn per se (Breydo et al., 2012; Lundvig, Lindersson, & Jensen, 2005). 
Interaction with dopamine stabilizes a particularly toxic aggregation intermediate (protofibril) 
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(Conway, Rochet, Bieganski, & Lansbury, 2001). Under pathological conditions, a-syn is 
thought to exert cellular toxicity through a variety of mechanisms, largely involving interactions 
with cellular membranes (Breydo et al., 2012; Vekrellis, Xilouri, Emmanouilidou, Rideout, & 
Stefanis, 2011). 
Intriguingly, while it was recognized that mutations in the SNCA cause PD, it was 
subsequently found that duplications and triplications of the locus containing wild-type (WT) 
SNCA also cause PD (Singleton et al., 2003). These locus multiplications lead to 1.5- to 2-fold 
increases in WT SNCA mRNA and protein levels relative to normal SNCA expression levels 
(Miller et al., 2004). Individuals with SNCA locus triplication develop disease with an earlier 
onset and more severe phenotype than those with gene duplication (Ross et al., 2008). This 
suggests that there is a “dosage effect” whereby higher levels of a-syn, whether WT or mutant, 
are associated with more toxicity. (Breydo et al., 2012) 
It follows that if excessively high levels of WT a-syn are toxic per se, then any event 
contributing to increases in a-syn levels – e.g. decreased degradation of a-syn or increased 
transcription/translation of SNCA – may be involved in PD pathogenesis.  In fact, there is 
evidence suggesting that both of these mechanisms are involved in PD. Alpha-synuclein can be 
degraded through various pathways depending on its ubiquitination state (Rott et al., 2011). 
These include degradation via the ubiquitin-proteasome system and lysosomal degradation via 
chaperone-mediated autophagy, both of which appear to be dysregulated in PD and are 
themselves targets of a-syn toxicity (Cuervo, Stefanis, Fredenburg, Lansbury, & Sulzer, 2004; 
Mazzulli et al., 2011; Xilouri, Vogiatzi, Vekrellis, Park, & Stefanis, 2009). Furthermore, 
glucocerebrosidase (GBA1) – a lysosomal enzyme that causes Gaucher’s disease in homozygous 
(GBA-/-) individuals – has been identified as a genetic modifier of a-syn levels and toxicity in 
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heterozygous (GBA+/-) individuals and confers an approximately 5-fold increased risk of PD 
(DePaolo, Goker-Alpan, Samaddar, Lopez, & Sidransky, 2009; Marder, 2010). It is thought that 
GBA hypofunction in GBA+/- individuals leads to decreased lysosomal degradative activity with 
consequent accumulation and aggregation of a-syn (Cookson, 2011; T. M. Dawson & Dawson, 
2011). 
Dysregulation of SNCA at the transcriptional level also appears to be an important factor 
in a-syn accumulation and toxicity in PD. Chiba-Falek and colleagues examined SNCA mRNA 
levels in human post-mortem tissue homogenates and found significantly increased SNCA in PD 
SNc as compared to control (Chiba-Falek, Lopez, & Nussbaum, 2006). Gründemann and 
colleagues investigated the content of SNCA mRNA specifically within nigral dopamine neurons 
in post-mortem human brain using laser-capture microdissection and found that SNCA mRNA is 
significantly increased in surviving nigral dopamine neurons in PD relative to controls 
(Gründemann, Schlaudraff, Haeckel, & Liss, 2008). McLean and colleagues have recently 
reported similar findings in PD post-mortem specimens (J. R. McLean, Hallett, Cooper, Stanley, 
& Isacson, 2011). Notably, some reports have failed to show increases in SNCA mRNA in PD 
SNc (Dacshel et al., 2007; DePaolo et al., 2009; Kingsbury et al., 2004; Marder, 2010). These 
discrepancies may be explained by technical issues regarding method of assessment or variability 
in the severity of disease in the samples. 
GATA transcription factors were the first transcription factor regulators of SNCA to be 
identified (see Section 1.3.4) and it has been proposed that they may contribute to PD 
pathogenesis by aberrantly increasing transcription of SNCA (and potentially other PD-relevant 
genes) (M. Chesselet, 2009; Scherzer et al., 2008). Additionally, two micro-RNAs (miRNA) 
have been identified as post-transcriptional down-regulators of SNCA in vitro (Doxakis, 2010; 
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Junn et al., 2009). In at least two reports, the levels of specific miRNAs have been reported as 
decreased in the PD SN relative to controls; however, more work is needed to confirm these 
findings and establish their relevance to a-syn accumulation in PD (Hebert & De Strooper, 2007; 
Kim et al., 2007). 
Cis-regulatory elements also appear to contribute to SNCA transcriptional dysregulation. 
Common sequence variants – single nucleotide polymorphisms (SNP) – in the 3’ untranslated 
region of SNCA were recently associated with an increased risk of PD in two large genome-wide 
association studies, one examining a population of European descent and the other a Japanese 
population (Satake et al., 2009; Simón-Sánchez et al., 2009). Additional studies have also shown 
that SNPs can influence SNCA levels in certain tissues and modify age of PD onset (Cardo et al., 
2011; Fuchs et al., 2007). A PD-associated dinucleotide repeat polymorphism (Rep1) has been 
identified 10 kb upstream of the SNCA transcriptional start site and leads to increased SNCA 
expression in cells (Chiba-Falek & Nussbaum, 2001; Cronin et al., 2009; Farrer et al., 2001; 
Maraganore et al., 2006; Pals et al., 2004). A recent epidemiological study has shown that 
individuals with the expanded Rep1 allele plus history of head trauma have a greater risk of 
developing PD than either factor alone, providing an example in support of genetic and 
environmental interactions contributing to PD (Goldman et al., 2012).  
Alpha-synuclein accumulation may not be simply a cell-autonomous event. For example, 
when the brains of PD patients who had received fetal mesencephalic tissue transplants came to 
autopsy they showed synuclein pathology (Lewy bodies) within dopaminergic neurons of the 
graft (Kordower, Chu, Hauser, Freeman, & Olanow, 2008a; Kordower, Chu, Hauser, Olanow, & 
Freeman, 2008b; Li et al., 2008). Since the grafts were from fetal tissue – and therefore not 
themselves expected to develop parkinsonian pathology – it was proposed that the pathology 
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spread from host to graft, either through noxious stimuli that initiate a-syn aggregation such as 
inflammation and/or through the cellular uptake of a-syn itself in a prion-like manner. Indeed, it 
was shown subsequently that a-syn can enter neurons from the extracellular space and participate 
in ‘permissive templating’, leading to aggregation of endogenous a-syn in vitro (Desplats et al., 
2009; Volpicelli-Daley et al., 2011). The stereotyped “spread” of Lewy body pathology that 
Braak has proposed to occur over the course of PD (Braak et al., 2003) may be mechanistically 
supported by these findings. (However, the affected regions are not connected mono-
synaptically, and the intervening connecting neurons seem to be unaffected by a-syn pathology.) 
Since endogenous a-syn pathology in PD patients appears to undermine cell transplant therapies, 
strategies to lower a-syn levels – either at the transcriptional or post-transcriptional level – are an 
active area of investigation. 
Leucine-rich repeat kinase 2 (LRRK2)  
Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) have been identified as the 
most common cause of familial PD (accounting for an estimated 5-10% of cases) as well as a 
relatively common cause of sporadic PD (an estimated 1-5% of cases) (Paisán-Ruı́z et al., 2004; 
Satake et al., 2009; Simón-Sánchez et al., 2009; Westerlund, Hoffer, & Olson, 2010; Zimprich et 
al., 2004). One of the LRRK2 mutations, G2019S, is remarkably common in certain populations. 
For example, in North African and Ashkenazi Jewish populations, up to 40% of familial and 
sporadic PD is associated with the G2019S mutation (Lees et al., 2009; Westerlund et al., 2010). 
This mutation has an age-dependent and highly variable level of penetrance, however. It has 
been estimated that the penetrance of the G2019 mutation is 28% at age 59, 51% at age 69, and 
74% at age 79 (Healy et al., 2008). Thus, this and other LRRK2 mutations may function more as 
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genetic risk factors than high penetrance disease genes in many cases. If so, there must be other 
factors, perhaps including environmental exposures, which influence risk of disease.  Clinically, 
patients with LRRK2 mutations are generally difficult to distinguish from patients with sporadic 
PD in that they exhibit similar age of onset, similar (if not more benign) signs and symptoms, 
and are generally responsive to L-DOPA treatment. Rarely, LRRK2 mutations are associated 
with dementia and a tauopathy that is not seen in typical PD. 
LRRK2 is a large gene (51 exons) that encodes a cytosolic serine/threonine kinase that 
likely acts in a complex with other proteins and is often found in association with membranes 
(e.g. endoplasmic reticulum, endosomes, mitochondria) in neuronal cell bodies, axons, and 
dendrites (Biskup et al., 2006). LRRK2 is unique in that it is a multi-domain protein that contains 
both a kinase domain and a GTPase domain in the same open reading frame (Kumar & Cookson, 
2011). How these domains interact to influence LRRK2 function under physiological and 
pathophysiological conditions is still under investigation.  PD-causative mutations have been 
localized to conserved regions throughout several disparate domains, and it is possible that 
mutations in different functional domains dysregulate LRRK2 in different ways.  This may 
account for the diverse neuropathological features of LRRK2 PD discovered upon autopsy: 
histopathology that ranges from nigral dopamine cell loss in the absence of Lewy bodies to 
nigral degeneration with Lewy body pathology involving the SNc as well as other structures – 
and may even include the presence of tau-positive neurofibrillary tangles or TDP43 
proteinopathy (Dickson et al., 2009; Zimprich et al., 2004).  
The most prevalent LRRK2 mutation, G2019S, occurs within the kinase domain and 
causes an increase in kinase activity (West et al., 2005). The increased kinase activity of G2019S 
mutants may induce pathogenic signaling cascades, however 43 LRRK2 mutations have been 
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associated with PD to date (8 confirmed pathogenic) and many of these do not alter LRRK2 
kinase activity.  Nevertheless, kinase-activating mutations have received the most attention and 
there is a great amount of effort to identify substrates of LRRK2-mediated phosphorylation and 
determine whether dysregulation of their corresponding pathways plays any significant role in 
PD pathogenesis from G2019S LRRK2 mutations. LRRK2 kinase inhibitors have been developed 
and show some success in ameliorating certain parkinsonian features in animal models (B. D. 
Lee et al., 2010; Z. Liu et al., 2011). 
Parkin 
Mutations in parkin, an E3 ubiquitin ligase, cause a recessive, early-onset, slowly progressive 
parkinsonism (Kitada et al., 1998). Mutations in parkin account for the majority (~50%) of early-
onset familial PD, and more than 100 distinct mutations have been identified (Westerlund et al., 
2010). Point mutations and deletions can present in a homozygous or compound heterozygous 
fashion, in any combination. Single heterozygous mutations have been found in some PD cases, 
but these are difficult to interpret in terms of causality. There are also reports that SNPs in parkin 
may contribute to some cases of sporadic PD (S. J. Chung et al., 2011). Clinically, parkin-
associated PD typically has an early onset (30s rather than 50-60s), a good response to L-DOPA, 
and a benign course. 
As an E3 ubiquitin ligase, parkin catazlyzes the transfer of ubiquitin to target proteins to 
either mark them for degradation by the ubiquitin proteasome system, or for non-degradative 
signaling purposes. Several putative parkin ubiquitylation substrates have been identified in 
vitro, but only some of these putative parkin targets accumulate in the brains of patients with 
pathogenic parkin mutations and none of these proteins is found to be significantly elevated in 
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parkin knockout animals, suggesting E3 ubiquitin ligase redundancy for some substrates. Though 
additional parkin substrates will likely be identified, so far, accumulation of particular parkin 
substrates does not appear to be the mechanism by which mutant parkin causes toxicity.  This 
leaves open the possibility that parkin mutations cause neurodegeneration via loss of a non-
degradative (signaling) function. 
Parkin has been implicated in mitochondrial maintenance, where it may, under some 
circumstances, play a role in selectively targeting depolarized mitochondria for mitochondria-
specific autophagic degradation (mitophagy) (Narendra, Tanaka, Suen, & Youle, 2008). 
Narendra and colleagues have shown in vitro that depolarization of mitochondria with an 
uncoupling agent results in translocation of cytosolic parkin selectively to depolarized 
mitochondria and that these mitochondria are subsequently removed in an autophagic process 
(Narendra et al., 2008). These findings have been replicated by others, and it appears that the 
presence of PINK1 on depolarized mitochondria is critical for proper translocation of parkin (see 
1.1.3.1.4).  What parkin is doing once it reaches mitochondria in order to seal their degradative 
fate is unresolved at this point, but may involve ubiquitylation of a key mitochondrial target 
protein involved in initiating mitophagy. It is important to note that although these results are 
intriguing, the studies have been carried out primarily in immortalized cell lines, and there is as 
yet little evidence that these events occur in bona fide neurons (Van Laar et al., 2011). 
PTEN-induced putative kinase 1 (PINK1) 
Mutations in PINK1 cause a rare form of early-onset autosomal recessive parkinsonism that is 
both clinically and neuropathologically similar to parkinsonism due to mutations in parkin 
(Valente, Abou-Sleiman, Caputo, Muqit, Harvey, Gispert, Ali, Del Turco, et al., 2004a). PINK1 
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is a nuclear-encoded, mitochondrial protein kinase.  Most mutations occur in or near the kinase 
domain and consequently disrupt the kinase activity of the protein (Hatano et al., 2004; Valente, 
Salvi, Ialongo, Marongiu, Elia, Caputo, Romito, Albanese, et al., 2004b). 
PINK1 knockout flies exhibit a phenotype of mitochondrial defects that is strikingly 
similar to that of parkin knockout flies and genetic rescue experiments demonstrated that parkin 
over-expression can rescue the PINK1 knockout phenotype, though the converse does not occur 
(Clark et al., 2006; J. Park et al., 2006). This indicates that PINK1 not only operates in the same 
genetic pathway as parkin, but also acts upstream of parkin.  Based on this finding and the 
possibility that parkin plays a role in targeting dysfunctional mitochondria for mitophagy (see 
above), efforts have continued to delineate the role of PINK1 and parkin in this process – 
reviewed recently by Youle and Narendra in (Youle & Narendra, 2011). More work is required – 
particularly in neurons – to define the biochemical pathway responsible for PINK1/parkin-
dependent mitophagy in response to mitochondrial membrane impairment, but these studies have 
enhanced our understanding of PINK1 and parkin dysfunction in genetic forms of PD, and have 
further implicated mitochondrial dysfunction in the pathogenesis of PD. 
DJ-1 
Homozygous or compound heterozygous mutations in DJ-1 are an extremely rare cause of early-
onset, recessive parkinsonism (Bonifati et al., 2003), the neuropathology of which is unknown.  
DJ-1 is a redox-active protein expressed predominantly in astrocytes (at least in humans) that 
senses oxidative stress through modification of a critical cysteine and is subsequently 
translocated to mitochondria to protect the cell against oxidative stress (Canet-Aviles et al., 
2004). Mutations lead to misfolding, decreased stability, and degradation of the protein, resulting 
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in lower protein levels and thereby loss of function (Westerlund et al., 2010). Consensus is 
lacking as to how exactly DJ-1 orchestrates cytoprotection as the protein has been proposed to 
have a broad range of functions – e.g. RNA binding, stabilization of antioxidant transcription 
factors, and acting as a cysteine protease.  A role in signaling may explain these disparate 
observations, but details are still lacking. Despite these uncertainties, DJ-1 represents the third 
‘mitochondrial’ protein (after parkin and PINK1) whose loss of function results in a parkinsonian 
syndrome and, as such, helps reinforce the concept that mitochondrial dysfunction is central to 
PD pathogenesis. 
1.1.3.2 Environmental Factors and PD 
The term “environmental factor” refers to any influence that originates from outside the genome.  
Environmental factors include compounds in the air we breathe, substances we ingest, and 
certain metabolic changes induced by activities we perform. When considering chemical 
toxicants, there is a tendency to focus on man-made synthetic compounds, but humans are 
exposed on a daily and chronic basis to a huge number of naturally-occurring compounds in the 
atmosphere and in our food and water supplies. If environmental factors influence PD 
pathogenesis or progression, they may do so either through direct action on the cells that die in 
PD, or through indirect actions – for example, by altering metabolism of other substances, 
permeabilizing the blood-brain barrier, activating the immune system, or altering hormonal 
signaling.  
The list of environmental factors associated with PD continues to grow in number and 
diversity.  Unfortunately, scientific support for many of the factors posited to contribute to PD 
risk is sometimes limited to retrospective (case-control) studies of low sample size that might be 
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biased by the subjects’ ability to recall past exposures or activities.  These studies can, at best, 
uncover associations, but they cannot prove causality.  Demonstration that any of these factors 
might be causative requires the use of in vitro and in vivo disease modeling. 
1.1.3.3 Age, Gender, and Lifestyle Factors 
Among the factors most commonly associated with PD are increased age and male gender.  The 
risk for sporadic PD increases in an age-dependent manner across all populations studied to date, 
and the penetrance of some monogenic forms of PD has also been shown to increase with age 
(e.g the G2019S mutation in LRRK2). The odds ratio for risk of developing PD in men compared 
to women is consistently found to be approximately 1.5 – 2.0 (Elbaz et al., 2002; Elbaz & 
Tranchant, 2007). It is unknown whether the underpinning for this difference is biological (e.g. 
hormonal), sociological (e.g. occupational) or both. Lifestyle and dietary habits seem to exert an 
influence over one’s risk of developing PD as well.  There are numerous reports of an inverse 
association between tobacco use and PD that is dose-dependent. Whether this effect is due to a 
component of tobacco or a feature related to tobacco users themselves remains to be determined; 
however, there is evidence that nicotine alters various components of dopaminergic systems and 
may protect against dopaminergic cell death (Quik, O'Leary, & Tanner, 2008). Caffeine 
consumption—from coffee and tea alike—is also associated with a dose-dependent decrease in 
risk of developing PD in some studies (Ascherio et al., 2001). Lastly, environmental factors 
related to occupational exposures – including pesticides (see below), industrial solvents (Gash et 
al., 2008; M. Liu et al., 2010), metals (Guilarte, 2011), and head trauma – have been associated 
with the development of PD or parkinsonism (Cannon & Greenamyre, 2011). 
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1.1.3.4 Pesticides 
Initial investigation into the relationship between pesticides and PD began after several young 
intravenous drug users residing in the same area of California developed acute onset of severe 
parkinsonism that proved to be irreversible (Langston, Ballard, Tetrud, & Irwin, 1983). It was 
discovered that they had mistakenly injected 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine 
(MPTP), a potent neurotoxin that easily crosses the blood brain barrier into the brain, where its 
toxic metabolite selectively poisons dopaminergic neurons.  This work provided the first proof-
of-principle that an ‘environmental’ toxin could produce parkinsonism in man. Because MPTP 
acts by inhibiting mitochondrial function, this work also provided the first clue that 
mitochondrial impairment might be important in PD pathogenesis. Furthermore, a structural 
similarity between MPTP and the commonly used herbicide, paraquat, was noted (although more 
recent studies have shown that they have different mechanisms of toxicity). Nevertheless, based 
in part on this structural similarity, subsequent epidemiological studies found an association 
between agricultural pesticide use and death from PD (Ritz & Yu, 2000). 
An increasing number of studies have reported an association between pesticides and PD; 
however, several issues make such studies difficult to perform and hard to interpret 
unambiguously.  First, they often rely on reports from individual study subjects on the duration, 
amount, and type of pesticide exposure; thus, there may be reporter (recall) bias.  Second, the 
accuracy of clinical diagnosis of PD is variable, and depends in large part on the training and 
experience of the investigators. Third, professional pesticide users are often exposed to several 
pesticides over time rather than a single agent.  Lastly, the degree of exposure can vary based on 
the duration of use, the concentrations handled, and the safety precautions taken by pesticide 
handlers.  Nonetheless, meta-analyses find an increased incidence of PD among subjects who 
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have a history of exposure to pesticides.  The odds ratio for an association between professional 
pesticide use and PD development was 1.9 (95% CI = 1.5-2.5) in one such meta-analysis 
(Priyadarshi, Khuder, Schaub, & Shrivastava, 2000). Living in rural areas and drinking water 
from wells have both been associated with an increased risk of PD in some studies, and these 
associations are thought to be due to pesticide exposure. 
Identifying individual pesticides that are associated with PD has been challenging for the 
aforementioned reasons, but recent well-designed studies have done so (Costello, Cockburn, 
Bronstein, Zhang, & Ritz, 2009; Kamel et al., 2006). In a case-control study involving 368 PD 
cases and 341 controls from the same area, Costello and colleagues used state records of 
pesticide use over a 25-year period and corresponding land maps where these pesticides were 
used in order to remove recall bias (Costello et al., 2009). They found a 75% increased relative 
risk for PD (95% CI = 1.13-2.73) in subjects who were exposed to paraquat and maneb (a 
fungicide that is often used concomitantly with paraquat) (Costello et al., 2009). Interestingly, 
subjects younger than 60 years old at the time of exposure who were exposed to either of these 
agents alone had a significantly higher risk of PD with an odds ratio (OR) of 2.27 (95% CI = 
0.91-5.70) (Costello et al., 2009). This risk was significantly elevated when these younger 
subjects were exposed to both paraquat and maneb (OR = 4.17, 95% CI = 1.15-15.16) (Costello 
et al., 2009). In another report, Kamel and colleagues used data from the Agricultural Health 
Study, a large self-report study examining pesticide exposure and PD, and found an increased 
risk of PD associated with application of four individual pesticides: dieldrin, maneb, paraquat, 
and rotenone (Kamel et al., 2006). 
Since two prominent features of cellular and animal models of PD are mitochondrial 
complex I inhibition and generation of oxidative stress, Tanner and colleagues focused a recent 
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epidemiological study on rotenone and paraquat – two pesticides known to act via these 
respective mechanisms (Tanner et al., 2011). They found that pesticide applicators have an 
increased risk of developing PD after exposure to rotenone (OR = 2.5, 95% CI = 1.3-4.7) or 
paraquat (OR = 2.5, 95% CI = 1.4-4.7) (Tanner et al., 2011). These findings are significant 
because they strengthen the relevance of the pathogenic mechanisms (mitochondrial complex I 
inhibition and oxidative stress) in experimental models of PD as well as animal models of PD 
that use these toxicants. 
1.1.3.5 The Rotenone Rat Model of PD 
Sub-chronic administration of the pesticide rotenone, a lipophilic mitochondrial complex I 
inhibitor, to rats reproducibly induces many of the hallmark behavioral, neurochemical, and 
neuropathological features of PD, as well as several non-motor features of human PD, including 
gastrointestinal dysfunction (Betarbet et al., 2000; Greenamyre, Cannon, Drolet, & 
Mastroberardino, 2010). Rotenone also causes a-syn accumulation, aggregation and oxidation as 
well as mitochondrial translocation of DJ-1 (Betarbet et al., 2000; 2006; Cannon et al., 2009). 
Iron accumulation in SN is a well-recognized feature of PD and is reproduced in the rotenone rat 
and monkey models of PD (Mastroberardino et al., 2009). Using these models, we found that the 
iron import protein, transferrin receptor 2 (TfR2), is upregulated in dopaminergic neurons in the 
SNc, which provides a plausible mechanism for the iron accumulation observed in these cells 
(Mastroberardino et al., 2009). This finding was then confirmed in post-mortem human PD SNc 
specimens (Mastroberardino et al., 2009). Therefore, the rotenone model not only recapitulates 
many key features of human PD, it is also predictive of features that may be critical to 
pathogenic processes. 
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1.1.3.6 Common Mechanisms? 
Although the etiology of the vast majority of PD cases remains incompletely understood, the use 
of cellular and animal models based on some of the monogenic forms PD and environmental 
toxins has elucidated several key cellular pathways that appear to be central to PD pathogenesis. 
Several lines of evidence support a role for mitochondrial impairment in PD: First, cells taken 
from patients with sporadic PD show complex I impairment relative to controls (Banerjee, 
Starkov, Beal, & Thomas, 2009; Barroso et al., 1993; Haas et al., 1995). Second, two of the main 
neurotoxic models of PD utilize complex I inhibitors – MPTP and rotenone – to produce a 
parkinsonian phenotype (Betarbet et al., 2000; Jackson-Lewis, Blesa, & Przedborski, 2012). 
Third, the three genes known to cause autosomal recessive parkinsonism – i.e. parkin, PINK1, 
and DJ-1 – have been implicated in maintaining mitochondrial function in the face of cellular 
stress, and their mutation leads to mitochondrial dysfunction (see 1.1.3.1.3-1.1.3.1.5). Fourth, 
there is evidence of mitochondrial DNA damage in PD and models thereof (Arthur, Morton, 
Dunham, Keeney, & Bennett, 2009; Sanders et al., n.d.). Associated with the mitochondrial 
dysfunction in PD is oxidative stress, which is another central feature of PD (Tsang & Chung, 
2009). 
Disruption of protein homeostasis is another critical feature of PD supported by several 
findings both in PD patients and in animal and cellular models of PD. First, the 
neuropathological hallmark of PD is the Lewy body, which is an intracellular insoluble inclusion 
of aggregated proteins, including a-syn. Lewy bodies arise when accumulated proteins either 
outstrip the ability of the cell to degrade them and/or where the degradative machinery is 
dysfunctional. Second, there is evidence that the ubiquitin proteasome system and autophagy – 
key cellular degradative systems – are impaired in PD. Third, mutation and locus multiplication 
  20 
of SNCA, which encodes the aggregation-prone protein a-syn, cause PD with clinical severity 
and onset depending on gene copy number. Taken together, these converging lines of evidence 
strongly support a role for dysregulation of protein homeostasis in the pathogenesis of PD. 
1.1.4 PD Treatment 
There is currently no treatment that successfully modifies the progression of PD. Instead, PD 
therapy is limited to symptomatic treatment of motor symptoms. Given that many of these motor 
symptoms arise due to degeneration of nigrostriatal fibers and consequent dopamine depletion in 
the striatum, the majority of PD therapies are intended to replenish dopamine. These drugs fall 
into three general categories: 1) dopamine agonists, 2) inhibitors of the dopamine-catabolizing 
enzymes, and 3) the dopamine precursor, L-DOPA. L-DOPA is the most effective treatment for 
motor symptoms, but continued use leads to loss of efficacy and the development of dyskinesias 
in more than 80% of patients, which can be just as debilitating for patients as the bradykinesia or 
tremor for which they were initially given the drug (Yacoubian & Standaert, 2009). Deep-brain 
stimulation (DBS) is a surgical intervention in which an electrode is introduced into a brain 
region (usually the subthalamic nucleus) to modulate inhibitory tone in the basal ganglia, 
essentially accommodating for the loss of dopaminergic neurotransmission from the SNc 
(Pizzolato & Mandat, 2012). It is effective in treating some motor symptoms and reducing 
dependence on L-DOPA, but not all patients are good surgical candidates for DBS (Pizzolato & 
Mandat, 2012). Since none of the therapies modifies disease course or alleviates the (often more 
debilitating) non-motor symptoms of PD, novel therapeutics are desperately needed. 
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Despite the divergent causes implicated in the development of PD, the common set of 
dysregulated pathways that appear to be central to PD pathogenesis (see 1.1.3.2.4) have provided 
a rational basis for drug development. Unfortunately, all drugs tested to date in clinical trials – 
including antioxidants, anti-apoptotic drugs, anti-inflammatory drugs, mitochondria-stimulating 
drugs – have failed to demonstrate meaningful clinical neuroprotection (i.e. modification of 
disease course) (Meissner et al., 2011). This disappointing outcome has been attributed to several 
potential issues. First, there is no animal model that fully and accurately recapitulates PD 
pathobiology. With this limitation comes poor predictive power for determining whether a 
therapy will fare well in human clinical trials (Yacoubian & Standaert, 2009). Second, the design 
of clinical trials may be limiting investigators’ ability to determine whether a therapy is 
neuroprotective. Strong placebo effect (which is common in PD clinical trials, (Goetz et al., 
2008)), small (underpowered) trials, inadequate outcome measures, short-duration studies, and 
symptomatic effects of the experimental therapies can all mask neuroprotection, leading to 
failure of the therapy in clinical trials (Meissner et al., 2011; Yacoubian & Standaert, 2009). 
Third, the lack of surrogate indicators of nigrostriatal system preservation (e.g. brain imaging) 
make it difficult to determine whether an experimental therapy is indeed neuroprotective or just 
exerting symptomatic effects. Lastly, inclusion and exclusion criteria for these clinical trials are 
not based on specific PD sub-types (e.g. the sub-types described in (van Rooden et al., 2011), so 
a therapy that may be neuroprotective in one population of PD patients but not another cannot be 
determined. 
While the majority of PD drugs in the market act on the dopamine system, the majority of 
drugs in PD clinical trials have non-dopamine system targets (Meissner et al., 2011). Among the 
more exciting non-dopaminergic drugs in development at the pre-clinical trial stage, are 
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inhibitors of LRRK2 kinase activity (for patients with the LRRK2 G2019S mutation), various 
therapies attempting to lower a-syn toxicity (e.g. via gene silencing, stimulation of a-syn-
degrading pathways, and aggregation inhibitors), and gene therapy approaches to deliver trophic 
factors (see 1.2.3) (Meissner et al., 2011; Yacoubian & Standaert, 2009). This shift from 
dopaminergic drugs to drugs targeting specific pathways relevant to disease pathogenesis seems 
like an appropriate response to the unmet needs in PD therapy; however, certain measures must 
be taken in order to ensure their best chances of success in clinical trials. In addition to clinical 
trial reform and refinement of PD animal models, discovery of a biomarker (or set of 
biomarkers) that can diagnose PD at a pre-symptomatic stage will be a significant therapeutic 
advance. Other biomarkers might track with disease progression or allow an assessment of 
therapeutic “target engagement”. Such biomarkers would allow for earlier intervention and likely 
a greater dynamic range for testing therapeutic benefit. 
1.2 GENE THERAPY 
1.2.1 Introduction 
The aim of gene therapy is to modulate gene expression therapeutically in vivo by delivering 
nucleic acids to cells of interest. Gene therapy may involve delivery of genes to compensate for 
those that are deficient in a patient (e.g. loss-of-function disorders), or nucleic acids to suppress 
the expression of endogenous genes (e.g. gain-of-function disorders). Just as there is a wide 
range of available nucleic acids that can be used depending on the therapeutic goal, there are also 
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different options for delivery systems. For in vivo delivery to brain, viral vectors are most 
commonly employed. This is for several reasons, among them: 1) they have manipulable 
genomes that can be engineered for the expression of nucleic acids of interest, 2) they can be 
infused systemically or into focused regions depending on the need, 3) and they can be selected 
based on their natural tropism for certain cell types or engineered to preferentially target certain 
cell populations. 
Viral vectors that are commonly used for gene therapy applications include: lentiviruses, 
retroviruses, adenoviruses, adeno-associated viruses (AAV; see 1.2.2), and herpes simplex 
viruses. They differ in their basic biology, the target cell populations that they transduce, and 
their packaging capacity, and are exploited for different features depending on the therapeutic 
requirement. Since this dissertation involves the use of AAV2, we will restrict our discussion to 
AAV vectors. 
1.2.2 Adeno-associated Virus (AAV) 
Adeno-associated viruses are members of the Parvoviridae family, which are small, single-
stranded DNA-containing viruses that lack an envelope (Giacca, 2010). They are prevalent in 
various species and are not associated with any disease (Giacca, 2010). At least 80% of adults 
have been infected with AAV and have antibodies against it (Giacca, 2010). There are over 100 
different genetic variants (serotypes, AAV1-AAVn) that differ mostly in the protein composition 
of their capsids. Capsid proteins are the main determinant of viral tropism since it is they that 
interact with cell surface antigens to mediate adsorption and internalization of viral nucleic acids. 
For the most part, the cell surface antigens that AAV capsid proteins recognize are ubiquitously 
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expressed. For example, AAV2 recognizes heparin sulfate proteoglycans as well as αvβ5 
integrin, FGFR1, and HFGR co-receptors. AAVs can differ not only in the cells they infect but 
also in their mode of transmitting their genome into the target cells. 
The AAV genome is small (~4.7 kb) and consists of two open reading frames: a rep gene 
whose products are necessary for viral replication and a cap gene whose proteins compose the 
viral capsid (Giacca, 2010). Importantly, the coding region is flanked by 145-nucleotide inverted 
terminal repeat (ITR) sequences, which are required for all AAV functions (Giacca, 2010). For 
naturally occurring AAVs to replicate they depend on either co-infection with other “helper” 
viruses (e.g. adenovirus) or treatment with chemical agents (Giacca, 2010). This fact is exploited 
when engineering an AAV vector for use as a gene therapy agent. 
AAV vectors are made by removing the entire viral genome (rep and cap genes) – except 
for the required ITR sequences – and cloning into their place a transcriptional cassette of interest 
that is no larger than 4-4.5 kb. The transcriptional cassette may be, for example, a constitutive 
promoter, the coding region of a therapeutic cDNA (or short-hairpin RNA), and a poly-A 
termination sequence. Since the viral genome now lacks the rep gene (required for replication 
and integration into the host genome) and the cap gene (required to form the viral capsid), viral 
production requires either co-infection of cells with a virus that provides these necessary 
cassettes or transfection of cells with a plasmid containing the cassettes. The cap cassette (which 
determines serotype) can be chosen based on the cell population intended for therapeutic AAV 
transduction. The presence of these “helper” cassettes allows for productive replication of 
recombinant virus, but these cassettes do not enter the recombinant viral genome. Therefore, the 
purified recombinant vector lacks the ability to replicate and make viral capsid per se. 
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When recombinant AAV vectors infect (transduce) their target cells, the viral genome 
does not integrate into the host genome; instead it remains transcriptionally active as an episome. 
This feature is advantageous over other viral vectors (e.g. lentiviruses) whose genome integrates 
into host DNA with the associated risk of insertional mutagenesis. Another advantage of the viral 
genome staying in an episomal form is that the therapeutic genes are less frequently methylated 
(and hence suppressed) by endogenous mechanisms, allowing expression of therapeutic genes to 
persist for long periods of time (to at least 8 years in non-human primates, (Hadaczek, Eberling, 
Pivirotto, Bringas, Forsayeth, & Bankiewicz, 2009a)). 
1.2.3 Gene Therapy in PD 
There are three general categories of gene therapy currently being evaluated in PD clinical trials. 
The first, like most of the PD drugs used clinically, involves delivering genes to restore 
dopamine production and release in the striatum. The second involves correcting basal ganglia 
signaling in a manner similar to DBS. The third category of gene therapy for PD delivers a 
growth factor in an attempt to prevent further degeneration of dopaminergic neurons. 
The rationale in delivering genes that enhance endogenous dopamine production is to 
decrease reliance on L-DOPA, and therefore presumably decrease the likelihood of 
complications that frequently occur with long-term L-DOPA use (A. Björklund & Björklund, 
2011; T. Björklund & Kirik, 2009). In the first of these clinical trials, a lentivirus was used to 
deliver three genes involved in dopamine synthesis to the striatum of patients with advanced PD: 
tyrosine hydroxylase (TH, the rate-limiting enzyme), aromatic amino acid decarboxylase 
(AADC), and GTP cylcohydrolase-1 (which is required for the synthesis of a cofactor necessary 
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for TH enzymatic activity). There has also been a smaller study in which AADC alone was 
delivered to the striatum of patients with advanced PD using an AAV vector (Mittermeyer et al., 
2012). In this case, dopamine synthesis would only occur when the L-DOPA substrate is present, 
thereby allowing clinicians to safely titrate dopamine production by adjusting the L-DOPA dose 
they administer. 
The loss of dopamine release from degenerating nigrostriatal fibers in PD results in 
overactivity of the subthalamic nucleus (STN) and down-stream dysregulation of basal ganglia 
signaling. DBS improves motor features of PD by normalizing subthalamic nucleus activity 
electrically. STN activity may also be normalized via local production of the inhibitory 
neurotransmitter, GABA. A small phase II clinical trial in which the gene for the rate-limiting 
GABA synthesis enzyme, glutamic acid decarboxylase (GAD), was delivered to the STN of PD 
patients via AAV2 was recently completed (LeWitt et al., 2011). Patients who received the viral 
infusion showed a statistically significant improvement in motor symptoms at 6 months as 
compared to patients who received sham surgery (LeWitt et al., 2011). 
Neurturin is a member of the transforming growth factor-β family of growth factors. Its 
closely-related family member, glial cell line-derived neurotrophic factor (GDNF), has been 
shown to be required for the survival of catecholaminergic neurons, providing a rationale for 
delivery of such growth factors (Pascual et al., 2008). In fact, pre-clinical trials in the non-human 
primate MPTP model of PD showed that delivery of neurturin is neuroprotective (Herzog et al., 
2009; Kordower et al., 2006). A clinical trial was undertaken in which PD patients received 
intraputamenal infusions of AAV2 containing the neurturin gene (Marks et al., 2010). At 12 
months, infusion of AAV2-neurturin did not yield any improvement over sham surgery on a 
motor rating scale, though there was some improvement in secondary measures of the study 
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(Marks et al., 2010). The difference in outcome between the human PD and non-human primate 
MPTP studies has been ascribed to poor axonal transport of the therapeutic gene from the site of 
infusion (putamen) to the cell bodies in the SNc, a problem that could potentially be 
circumvented by infusing the viral vector instead directly into the SNc (Lewis & Standaert, 
2011). 
Although no PD gene therapy clinical trial has shown success in conferring 
neuroprotection, there are many approaches that are showing promise in pre-clinical 
development. Particularly attractive are therapeutic approaches that target cellular pathways 
known to be dysfunctional in PD, such as a-syn accumulation. Recently, we used AAV2 to 
deliver shRNA against SNCA to the rat SNc and found robust neuroprotection against rotenone, 
suggesting that this may be a therapeutically beneficial approach for PD patients (Cannon et al., 
n.d.). 
1.3 GATA TRANSCRIPTION FACTORS 
1.3.1 Basic Biology 
GATA transcription factors play important roles as master regulators in the development and 
maintenance of various organ systems. The GATA factor family comprises GATA factors 1-6, 
which are zinc-finger transcription factors that bear a high degree of sequence and structural 
homology (Bresnick, Katsumura, Lee, Johnson, & Perkins, 2012). GATA factors 1 and 2 are 
largely involved in hematopoiesis, though GATA2 also plays important roles in various other 
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tissues, including brain. GATA3 functions as a master regulator in immune system development, 
where it is critical to T-cell lymphopoiesis (Hosoya, Maillard, & Engel, 2010); it is also 
important for development of some neuronal populations (Nardelli, Thiesson, Fujiwara, Tsai, & 
Orkin, 1999). In contrast to these “hematopoietic” GATA factors, GATA4/5/6 are important for 
visceral organ development. Each GATA factor recognizes the consensus sequence, WGATAA, 
which is referred to as a GATA element (T. Fujiwara et al., 2009). GATA factors recognize 
many of the same loci, though there are some GATA elements that are recognized specifically by 
one GATA factor and not another – e.g. GATA1- or GATA2-specific GATA elements – likely 
due to the presence of cis regulatory elements and/or co-factors (T. Fujiwara et al., 2009). 
Because they are short sequences, GATA elements abound in the genome (there are an 
estimated 7 million motifs) (Bresnick et al., 2012). However, very few GATA elements (<1%) 
are actually occupied by GATA factors and influence gene expression (Bresnick et al., 2012). 
The majority of occupied, functional GATA elements are located outside of the proximal 
promoter, often ≥ 1kb up- or downstream; the most frequent occupied GATA elements are in 
introns and distant enhancers (T. Fujiwara et al., 2009). GATA elements do not have an absolute 
requirement for cis elements in order to bind GATA factors, but cis elements frequently do 
appear to influence GATA element functionality, often from a long distance away (Pi et al., 
2010). Specific chromatin signatures in the form of post-translational histone modifications mark 
occupied GATA elements, however it is unclear whether this epigenetic modification occurs 
prior to or as a result of GATA factor binding (Bresnick et al., 2012). Occupancy and function of 
GATA elements are also influenced by trans-acting factors, such as transcriptional co-activators 
or co-repressors, which are likely cell type-dependent and bind chromatin in multi-protein 
complexes containing GATA factors (T. Fujiwara et al., 2009). 
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To add a further level of complexity to GATA factor transcriptional regulation, 
individual GATA factors can reciprocally regulate each other in some contexts and can also exert 
qualitatively different effects at the same GATA element. These forms of regulation are 
exemplified by GATA “switch sites,” at which a GATA factor exerting positive regulation on a 
gene can be displaced by another GATA factor that suppresses expression of the same gene, or 
vice-versa (Snow et al., 2011). GATA switch sites are commonly used to drive wide-ranging 
changes in gene expression, often at cell fate decision points, such as differentiation. A classic 
example of GATA factor switching occurs during erythropoiesis, where GATA2 positively 
regulates its own expression until GATA1 levels rise and suppress GATA2 expression (Bresnick, 
Lee, Fujiwara, Johnson, & Keles, 2010). Dynamic exchange of GATA1 and GATA2 at GATA 
switch sites occurs at up to one third of occupied GATA elements (Dore, Chlon, Brown, White, 
& Crispino, 2012). The result is a major shift in transcriptional output, from GATA2-regulated 
gene sets to GATA1-regulated gene sets.  
For the most part, regulators of GATA transcription factor activity are unknown. There 
are conflicting reports about the importance of post-translational modifications – e.g. 
phosphorylation, acetylation, SUMOylation – in influencing GATA factor activity (Bresnick et 
al., 2012; Viger, Guittot, Anttonen, Wilson, & Heikinheimo, 2008). These discrepancies may be 
explained by the limitation of in vitro methods used to study GATA factor activity. Most in vitro 
activity studies are performed using GATA element-containing fragments linked to luciferase 
reporters, and often in conjunction with over-expression of GATA transcription factors. Because 
GATA factor occupancy and function are dependent on specific chromatin modifications and 
distal cis elements, the use of naked DNA in these experiments confounds interpretation. 
Similarly, over-expression of GATA transcription factors in vitro can lead to occupancy of 
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GATA elements that are normally unoccupied by endogenous GATA factors, again obscuring 
interpretation. 
Characterization of GATA factor target genes (and hence GATA factor function) has 
been aided by various genome-wide analyses in vitro, in which a given GATA factor-expressing 
cell type is subjected to chromatin immunoprecipitation sequencing (ChIP-seq) followed by gene 
expression profiling after specific silencing of a GATA factor (T. Fujiwara et al., 2009). This 
method allows for unbiased examination of GATA factor gene targets and furthermore 
determines whether the bound GATA elements are functional and what the nature of the 
regulation is (positive vs. negative). In hematopoiesis, GATA2 functions to preserve progenitor 
stem cells in an undifferentiated state whereas GATA1 is active in differentiation of 
erythrocytes, megakaryocytes, eosinophils, and mast cells (Wozniak et al., 2008). Germ-line 
deletion of either GATA factor results in embryonic lethality due to severe anemia (Pevny et al., 
1991; Tsai et al., 1994). The sets of genes that each regulates therefore relates to the master 
function that each drives – e.g. globin chain synthesis for GATA1 as immature erythroblasts start 
to produce hemoglobin. So far, most examination has been performed in hematopoietic cell lines, 
focusing on GATA1 and GATA2 gene targets (T. Fujiwara et al., 2009). However, examination 
of other cell types has revealed that GATA factor gene targets appear to be cell type-dependent, 
along with the co-factors and co-regulators they utilize. For example, whereas GATA2 target 
genes in hematopoietic cell lines relate to erythropoiesis, GATA2 target genes detected in an 
endothelial cell line suggest that GATA2 functions in inflammatory pathways (Linnemann, 
O'Geen, Keles, Farnham, & Bresnick, 2011). Importantly, no such characterization has been 
performed in vivo, so it is not clear to what degree the in vitro findings can be generalized. 
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1.3.2 GATA2 
Rat GATA2 has 6 exons, the first two of which contain alternative transcriptional start sites that 
are used to drive tissue-specific expression: hematopoietic and neuronal expression is driven by 
exon IS; expression in other tissues is driven by exon IG (A. Björklund & Björklund, 2011; 
Shimahara, Yamakawa, Nishikata, & Morishita, 2010). Exons 4 and 5, which contain the zinc-
fingers, are highly conserved across the six GATA factors. GATA2 has large untranslated 
regions (1967 bp of the 3,411-bp rat mRNA is non-coding), suggesting that post-transcriptional 
regulation may occur, however no such regulators have been convincingly identified to date. The 
main factor that positively regulates GATA2 transcription (at least in hematopoietic cell lines) is 
GATA2 itself, though there is dynamic interaction with GATA1, which suppresses GATA2 
(Bresnick et al., 2012). GATA2 protein is degraded by the proteasome and, in vitro experiments 
(again in hematopoietic cell lines) have shown that GATA2 half-life is approximately 1 hour, 
suggesting that post-translational regulation may also play a role in regulating GATA2 activity 
(Lurie, Boyer, Grass, & Bresnick, 2008; Minegishi, Suzuki, Kawatani, Shimizu, & Yamamoto, 
2005). 
Although the majority of investigations into GATA2 target genes (and hence function) 
have been conducted in hematopoietic systems, where GATA2 regulates gene sets related to 
erythroid phenotype, cell cycle, and autophagy (T. Fujiwara et al., 2009; Kang et al., 2012), 
GATA2 is also expressed in non-hematopoietic tissues, including: neurons (Kala et al., 2009), 
endothelial cells (Dorfman, Wilson, Bruns, & Orkin, 1992), placenta (Ma et al., 1997), the 
urogenital system (Zhou et al., 1998), and pituitary (D. F. Gordon et al., 1997). Of these 
additional cell types, genome-wide analysis of GATA2 target genes has only been carried out in 
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endothelial cells, where it was shown to regulate many genes related to endothelial cell 
phenotype and inflammation, in concert with the inflammatory gene regulator, AP-1 (Linnemann 
et al., 2011). This finding illustrates more generally that GATA transcription factors regulate 
target genes in a cell type-specific manner, which is likely influenced by the presence of 
additional regulatory factors. 
Mutations in GATA2 have been associated with various hematopoietic and non-
hematopoietic diseases. Four hematopoietic syndromes can arise from germline mutations in 
GATA2 and carry an increased incidence of myelodysplastic syndrome and acute myeloid 
leukemia, often with associated immune dysfunction (Dickinson et al., 2011; Hahn et al., 2011; 
Ostergaard et al., 2011). Features of these syndromes are explained by the critical and broad 
hematopoietic role that GATA2 plays. GATA2 SNPs have also been associated with increased 
risk for familial early-onset coronary artery disease (Connelly et al., 2006). This may be 
explained by the role that GATA2 has recently been shown to play in regulating inflammatory 
gene sets in endothelial cells since inflammation is a critical process in atherosclerosis 
(Linnemann et al., 2011). Lastly, high levels of (wild-type) GATA2 have been linked to 
increased risk of prostate cancer recurrence (Böhm, Locke, Sutherland, Kench, & Henshall, 
2009), suggesting that not only mutations but also aberrant levels of wild-type GATA2 may lead 
to cellular dysfunction and disease. 
1.3.3 GATA Factors in the Brain(T. Fujiwara et al., 2009; Lurie et al., 2008) 
The only GATA transcription factors that are normally expressed in mammalian brain are 
GATA2 and GATA3. They are expressed in regionally overlapping but not identical patterns at 
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embryonic and post-natal stages of development, where they generally appear to act as selectors 
of phenotype in post-mitotic neurons rather than as developmental drivers in neurogenesis. 
GATA2 and GATA3 expression is evident in midbrain nuclei, the raphe nucleus, cranial motor 
neurons, the pituitary, and spinal cord interneurons (Kala et al., 2009; Nardelli et al., 1999; 
Nozawa et al., 2009; Richter, Meurers, Zhu, Medvedeva, & Chesselet, 2009; Tsarovina et al., 
2004; Willett & Greene, 2011; Zhao et al., 2008). 
Within the midbrain, GATA2 is expressed in the superior and inferior colliculi, the 
substantia nigra pars reticulata (SNr), and the SNc. Nozawa and colleagues have demonstrated 
that two GATA elements in the GATA2 gene are necessary for inducing and maintaining GATA2 
expression in midbrain regions, with each playing unique roles within the superior colliculus and 
the inferior colliculus (Nozawa et al., 2009). GATA2 and GATA3 are not co-expressed in the 
same cells, although they are co-expressed in some of the same brain regions (Nozawa et al., 
2009). Notably, no in vivo reports have shown GATA factor expression in glia, though an in 
vitro report demonstrates expression of GATA2 and GATA3 in primary mouse cortical neurons 
(Wallach et al., 2009). GATA2 expression is turned on as neurons exit the cell cycle in 
embryonic development, but expression is also present in many nuclei in post-natal stages (Kala 
et al., 2009). Kala and colleagues showed that GATA2 acts as a GABAergic phenotype selector 
in various nuclei by regulating gene sets related to GABAergic neuronal phenotype (Kala et al., 
2009). In these cells, GATA2 regulates genes involved in the GABA synthesis pathway (e.g. 
GAD1 and GAD2) as well as other genes necessary for GABA production (Kala et al., 2009). 
Interestingly, conditional loss of GATA2 in these cells results in glutamatergic phenotype 
selection (Kala et al., 2009). Using conditional mutagenesis, they showed that GATA2 does not 
participate in progenitor cell patterning or other features of neurogenesis (Kala et al., 2009). 
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Therefore, it appears that the primary function of GATA2 in post-mitotic midbrain GABAergic 
neurons is to act as a selector gene, controlling large sets of genes related to GABAergic 
phenotype. 
Both GATA2 and GATA3 are expressed within the murine substantia nigra. A study using 
in situ hybridization (ISH) in mice to map GATA factor expression showed, within the SN, that 
GATA3 expression is confined to the SNr (Zhao et al., 2008). Richter and colleagues used laser-
capture microdissection on rat midbrain sections combined with quantitative RT-PCR to 
examine globin gene expression in SNc, and found that GATA2 is expressed in SNc 
dopaminergic and GABAergic cells, though this was not a focus of their study (Richter et al., 
2009). The role of GATA2 in SNc dopaminergic neurons has not been investigated and remains 
unknown. 
1.3.4 GATA Transcription Factors and PD 
Many lines of evidence from human PD support a central role for alpha-synuclein in PD 
pathogenesis: (i) SNCA mutations causes a rare form of PD, (ii) multiplications of the wild-type 
gene causes PD with dose-dependent severity, (iii) a-syn pathology marks the pathological 
process anatomically in the majority of PD cases, and (iv) a-syn accumulates in degenerating 
neurons in the majority of PD cases (section 1.1.3.1.1). Together, these facts suggest that 
lowering a-syn levels in PD patients would confer neuroprotection. However, surprisingly little 
is known about regulation of SNCA expression. 
Scherzer and colleagues approached this problem using an innovative approach to 
identify transcriptional regulators of SNCA (Scherzer et al., 2008). After finding that SNCA 
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mRNA was detectable in blood, the authors interrogated gene expression databases for over 
14,000 genes across blood samples from 22 healthy humans. They performed numerous pair-
wise comparisons to determine genes whose expression correlated with that of SNCA – i.e. genes 
whose expression was high when SNCA levels were high and low when SNCA levels were low. 
At the end of their analysis, following several validation steps with additional datasets, this group 
comprised 35 genes. 
The authors hypothesized that a transcription factor coordinately regulates this gene 
block, thus accounting for the correlated expression of its genes. Three of the genes in this 
expression block – erythroid 5-aminolevulinate synthase 2 (ALAS2), biliverdin reductase B 
(BLVRB), and ferrochelatase (FECH) – are genes involved in heme metabolism and one of them 
(ALAS2) is known to be regulated by the transcription factor GATA1 (Surinya, Cox, & May, 
1997). A transcription factor that putatively coordinately regulates SNCA and various genes 
involved in iron metabolism is intriguing given the fact that both SNCA (section 1.1.3.1.1) and 
iron pathways (Horowitz & Greenamyre, 2010b; Sian-Hülsmann, Mandel, Youdim, & Riederer, 
2011) are dysregulated in PD. 
GATA1 is not expressed in brain, but Scherzer and colleagues showed that GATA2 
protein is detectable in homogenates from human SN and cortex, two regions affected by a-syn 
pathology in PD (Scherzer et al., 2008). They then showed that GATA2 silencing in the human 
dopaminergic neural cell line, SH-SY5Y, leads to significant down-regulation of SNCA at both 
the mRNA and protein levels, suggesting that GATA2 positively regulates SNCA. The authors 
showed that this regulation results from GATA2 directly and specifically binding to one of the 
10 GATA elements in the SNCA locus. 
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In summary, the authors used a novel approach to identify and validate in vitro the first 
transcription factor shown to regulate SNCA expression. The in silico finding that GATA 
transcription factors may coordinately regulate the expression of SNCA and iron-related genes is 
particularly intriguing since both a-syn and iron are known to accumulate pathologically in 
vulnerable SNc dopaminergic neurons in PD. However, in order for GATA2 to be relevant to 
PD, it remains to be shown that it is expressed in these neurons and regulates SNCA in vivo as it 
does in vitro. 
If GATA2 coordinately and positively regulates SNCA and genes relevant to iron 
homeostasis in vivo, then GATA2 might be envisioned as a potential therapeutic target to 
ameliorate a-syn and iron pathologies simultaneously. If GATA2 is pathologically activated in 
PD such that it induces excessive SNCA and iron homeostasis gene expression, then inhibition of 
GATA2 may normalize levels of its downstream target genes. If GATA2 is not involved in the 
pathological up-regulation of these genes, GATA2 may nevertheless be a useful target for 
inhibition in order to attenuate the basal expression of these genes. While this connection to PD 
is attractive, it must first be determined whether GATA2 is expressed in the neuronal populations 
that pathologically accumulate a-syn and iron and degenerate in PD. 
1.4 HYPOTHESIS & EXPERIMENTAL DESIGN 
In this dissertation project, we test two hypotheses. Our first hypothesis is that GATA2 regulates 
SNCA in dopaminergic SNc neurons in vivo. In order to test this hypothesis, we create and 
validate viral vectors for the delivery of shRNA against rat GATA2 and assess SNCA expression 
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under conditions of GATA2 silencing in the rat SNc. In the Chapter 2, we confirm that GATA2 
regulates SNCA in vitro, as described previously (Scherzer et al., 2008) and we validate rat as a 
reliable model system for examining GATA2 regulation of SNCA in vivo. The Chapter 3 
describes the development and validation of the viral vector used to test our first hypothesis, 
which we test in the third data chapter. 
Our second hypothesis is that down-regulation of GATA2 in SNc dopaminergic neurons 
protects these cells from rotenone-induced degeneration in the rotenone rat model of PD. We test 
this hypothesis in Chapter 4, by silencing GATA2 in SNc using the viral vector and by assessing 
neuropathological endpoints related to nigrostriatal integrity and animal survival. 
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2.0  GATA2 REGULATES SNCA IN VITRO AND IS PRESENT IN RAT AND 
HUMAN BRAIN 
2.1 ABSTRACT 
GATA2 has been shown to positively regulate SNCA in a human dopaminergic neural cell line 
and is expressed in human SN and cortex, regions that are susceptible to a-syn pathology in PD. 
Together, these findings prompt the idea that GATA2 may play a role in PD pathogenesis, 
however whether this mode of regulation occurs in brain has not been investigated. In this 
chapter, we confirm the finding that GATA2 positively regulates SNCA in vitro, and validate the 
rat as a suitable model for examining GATA2 regulation of SNCA in vivo. We find that GATA2 
regulation of SNCA is conserved between human and rat, and we localize GATA2 expression to 
various regions of the adult rat midbrain, including the SNc, which we confirmed in human SNc. 
Together, these findings set the stage for testing the hypothesis that GATA2 positively regulates 
SNCA in vivo. 
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2.2 INTRODUCTION 
Given the central role that elevated levels of alpha-synuclein (SNCA, a-syn) play in PD 
pathogenesis, lowering the expression of SNCA within dopaminergic neurons of the SNc may be 
a reasonable therapeutic goal in PD. The lack of knowledge about transcription factors that 
regulate SNCA has hampered progress toward modulating SNCA expression at the transcriptional 
level. Recently, GATA transcription factors were shown to regulate SNCA positively and directly 
in a mouse erythroid cell line and in a human dopaminergic neural cell line (Scherzer et al., 
2008). For this mode of regulation to be relevant to PD, it must be demonstrated that GATA2 is 
expressed within neurons that exhibit synucleinopathy and degeneration in PD. Scherzer and 
colleagues have shown that GATA2 is present in human brain homogenates from SN and cortex 
– two regions that undergo degeneration in PD – but their methods did not allow for localization 
to particular cell types in these regions (Scherzer et al., 2008). To the best of our knowledge, 
there has been only one report of GATA2 expression within adult rat SNc dopaminergic neurons 
(Richter et al., 2009), and no localization studies performed in human SNc. A comprehensive 
description of GATA2 expression in adult midbrain in general and SNc dopaminergic neurons in 
particular is therefore necessary to lend relevance of this regulatory system to PD. 
In order to establish the relevance of GATA2 in PD, we sought first to replicate the 
findings of Scherzer and colleagues (Scherzer et al., 2008) and then to demonstrate that GATA2 
is expressed in SNc dopaminergic neurons. Our results confirm and extend their findings, by 
demonstrating that GATA2 positively regulates SNCA in the human dopaminergic cell line, SH-
SY5Y, as well as in the rat dopaminergic cell line, PC12. Importantly, we show that GATA2 is 
expressed in neurons within the rat midbrain, including dopaminergic neurons within the SNc; it 
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was also expressed in human SNc. Taken together, these data suggest that GATA2 may plausibly 
play a role in regulating SNCA expression in relevant neuronal populations in PD. These data 
also set the stage for in vivo investigations of GATA2 regulation of SNCA in rat. 
2.3 MATERIALS & METHODS 
2.3.1 Cell lines and reagents 
SH-SY5Y (#CRL-2266) and PC12 (#CRL-1721) cell lines were purchased from American Type 
Culture Collection (ATCC). PC12 cells were grown on dishes coated with mouse collagen IV 
according to manufacturer’s instructions (Trevigen, #3410-010-01). Dulbecco’s Modified Eagle 
Medium (DMEM) and OptiMEM Reduced Serum Medium (#31985-070) were purchased from 
Gibco. Small-interfering RNA (siRNA) against human GATA2 (Stealth RNAi siRNA Duplex 
Oligoribonucleotides #HSS178122) and Lipofectamine RNAiMAX transfection reagent 
(#13778-075) were purchased from Invitrogen. The human GATA2 siRNA sequence used was: 
5’-UGAAGAAGACGUCCACCUCGUCUGG-3’. (See section 3.3.2 for rat GATA2 siRNA 
sequence design.) Stealth RNAi Negative Control duplex siRNA was purchased from Invitrogen 
(#12935-300). All chemicals were purchased from Sigma, expect where noted otherwise. 
The following pre-validated human and rat QPCR primer sets were purchased from 
Applied Biosystems: GATA2 (PPH0245A-200, PPR48683A-200), alpha-synuclein (SNCA, 
PPH05943E-200, PPR42596A-200), transferrin receptor 2 (TFR2, PPH05762A-200, 
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PPR51159A-200), neurofilament light chain (NEFL, PPH02430A-200, PPR46667A-200), 
GAPDH (PPH00150E-200), and beta-actin (ACTB, PPR06570B-200). 
2.3.2 Transfection 
SH-SY5Y cells of low passage number (4-8) were seeded onto 6-well plates at a density 
of 750,000 cells/well in DMEM containing 10% FBS, pencillin (100 units/mL), streptomycin 
(100 μg/mL) and grown overnight at 37° C in 5% CO2. Cells were transfected the following day, 
at 40-60% confluency. Twenty minutes prior to transfection, media was removed and cells were 
gently rinsed with warm PBS. 1.5 mL warm OptiMEM was added per well and the plates 
returned to 37° C. Lipofectamine RNAiMAX was diluted 1:50 in OptiMEM, then combined with 
an equal volume of OptiMEM containing siRNA against human GATA2 and incubated at room 
temperature for 25 min. Solutions were then added drop-wise at 500 μL/well and returned to 37° 
C. OptiMEM was replaced with serum media 6-12 hours after transfection. Samples were 
collected 48 hours post-transfection. Transfection of PC12 cells with siRNAs against rat GATA2 
was performed as described above for SH-SY5Y cells. 
2.3.3 Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-QPCR) 
RNA was isolated from cells and purified using an RNeasy minikit (Qiagen #74104) according 
to manufacturer’s instructions. Only RNA of sufficient purity (A260/280 ≥ 2.0) was used for 
analysis. Reverse transcription was performed using an RT2 First Strand Synthesis kit (SA 
Biosciences, #C-03) according to manufacturer’s instructions. Quantitative PCR using the SYBR 
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green method with dissociation curve was performed on a Stratagene MX3000P machine. 
Sample reactions were prepared on 96-well PCR plates in technical triplicates using: 5 μL cDNA 
template, custom QPCR primer sets (SA Biosciences), and SYBR Green PCR Master Mix 
(Applied Biosystems #4309155) per 25 μL reaction. Triplicate wells containing reactions with 
no template cDNA were used as negative controls to assess purity of reagents. For SH-SY5Y, 
GAPDH was used as a housekeeping gene for normalization. For PC12, ACTB was used as a 
housekeeping gene for normalization. Fold-change was calculated based on means of threshold 
cycle (Ct) values from technical triplicates in each independent experiment using the ΔΔCt 
Method (fold-change = 2(-ΔΔCt)). 
2.3.4 Immunocytochemistry (ICC) 
Cells on poly-D-lysine-coated coverslips were fixed in 4% PFA (EM #15710-S, Electron 
Microscopy Sciences) in PBS (pH 7.4) for 20 min. at room temperature, then washed 3 x 10 min. 
in PBS (pH 7.4). Coverslips were then blocked for 1 hour in 10% normal donkey serum (NDS) 
in PBS containing 0.03% Triton-X (PBST). Primary antibodies were prepared in 1% NDS in 
PBST as follows: goat anti-human GATA2 polyclonal antibody (R&D Systems, #AF2046), 
1:2000; mouse anti-alpha-synuclein monoclonal antibody (BD Transduction Laboratories, 
#610787), 1:2000. Primary antibody incubation was carried out overnight at 4° C. Coverslips 
were washed 3 x 10 min. in PBS (pH 7.4), then incubated for 1 hour in the dark in secondary 
antibody solution containing 1% NDS in PBST and the following secondary antibodies: Alexa 
Fluor 488-conjugated donkey-anti-goat IgG antibody (Molecular Probes, #A-11055), 1:500; 
Cy3-conjugated donkey-anti-mouse antibody (Jackson Immunoresearch, #715165151), 1:500. 
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Following removal of secondary antibody solution, coverslips were incubated in bisBenzimide 
Hoechst 33342 1:5000  (Sigma, #B2261) in PBS (pH 7.4) for 3 min. at room temperature in the 
dark. Coverslips were washed 3 x 10 min. in PBS (pH 7.4) in the dark, then mounted onto 
Superfrost Plus (Fisher, #12-550-15) slides with aqueous mounting media and dried overnight in 
the dark at room temperature. 
2.3.5 Confocal Microscopy & Quantification of Fluorescence Intensity 
Images of the fluorescently stained cells were obtained on a laser scanning confocal microscope 
(Olympus, Japan) at 60X magnification. Acquisition parameters—laser intensity, pinhole 
diameter, detector gain, and amplifier offset—were optimized and subsequently used for 
acquisition of all images across all treatment conditions. Importantly, fluorescence intensity of 
all channels was optimized such that no saturated pixels were present in any channels. 
Three coverslips per condition were imaged and analyzed; for each coverslip, at least 
three 60X fields were acquired, each containing approximately 10 cells. Regions of interest 
(ROIs) were precisely drawn around somata using the confocal microscope image analysis 
software, Fluoview FV1000 (Olympus, Japan). Average fluorescence intensity was measured for 
each ROI and averages and standard error of the mean (SEM) were calculated for each condition. 
An unpaired, two-tailed Student’s t-test was used to compare normalized fluorescence intensity 
means between siNeg and siGATA2 conditions (α=0.05). 
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2.3.6 Animals 
Three male Lewis rats aged 7-9 months were housed and treated in accordance with National 
Institutes of Health guidelines and University of Pittsburgh Institutional Animal Care and Use 
Committee (IACUC)-approved protocols. For sacrifice, animals were deeply anesthetized with 
sodium pentobarbital then decapitated. Brains were fixed by transcardial perfusion with 100 mL 
of ice-cold PBS (100 mM, pH 7.4) followed by 200-400 mL of fresh (less than one week old), 
ice cold 4% paraformaldehyde (PFA), pH 7.4. Brains were removed and fixed overnight at 4° C 
in 4% PFA, then transferred to an ice-cold PBS solution containing 30% sucrose for 5 days. 
Brains were cut at 35 μm on a freezing microtome and stored at -20° C in cryoprotectant solution 
(100 mM PBS, 25% glycerin, 30% ethylene glycol, pH 7.4). 
2.3.7 in situ Hybridization (ISH) 
A 399-bp fragment from the 3’ untranslated region of rat GATA2 was PCR amplified from total 
rat brain RNA (Clonetech) using a Phusion High-Fidelity PCR kit (New England Biolabs) with 
the following primers (5’-3’): (forward) CCAGCAAATCCAAGAAGAGC, (reverse) 
AGGTGGCTTCAGCCAGACTA. The PCR product was gel purified and incubated at 70° C for 
10 min. with Taq polymerase and PCR buffer, including dNTPs. The fragment was introduced 
into a pCR2.1-TOPO vector (Invitrogen) by T-A cloning and purified plasmids from resulting 
clones were sequenced to determine orientation of the insert. A plasmid containing the insert in 
the sense direction and a plasmid containing the insert in the antisense direction were used for in 
vitro synthesis of anti-sense and sense complementary RNA (cRNA) probes using a MAXIscript 
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T7 kit (Ambion) supplemented with digoxigenin-labeled uracil ribonucleotides (Roche). 
Resulting cRNA probes were resuspended in formamide buffer (50% formamide, 25% 5X SSC-
DEPC, 25% H2O-DEPC) and stored at -20° C. 
ISH was performed on perfusion-fixed free-floating brain sections under RNAse-free 
conditions. Sections were washed in 12-well nuclease-free plates 4 x 10 min. in DEPC-treated 
PBS (PBS-DEPC) to remove cryoprotectant. Active DEPC treatment of (0.1%, v/v; Sigma 
D5758) in PBS was performed in 24-well nuclease-free plates 2 x 15 min. followed by a 15-min. 
incubation in 5X SSC-DEPC. Sections were re-fixed in 4% PFA-DEPC for 20 min., then washed 
2 x 5 min. in PBS-DEPC. Blocking of non-specific nucleic acid interactions was performed by 
incubating sections in UltraHyb Ultrasensitive Hybridization Buffer (Ambion, #AM8670) 
containing Torula RNA at a final concentration of 1mg/mL (Sigma, #R6625) for one hour at 68° 
C, rocking. Antisense or sense cRNA probes for rat GATA2 were used at a concentration of 300 
ng/mL in pre-warmed UltraHyb Ultrasensitive Hybridization Buffer and incubations were 
carried out at 68° C, wrapped in plastic to prevent evaporation, rocking overnight. 
Following hybridization, sections were washed with the following buffers prepared from 
20X SSC (Ambion, #AM9763) in molecular biology-grade water (Sigma): 2X SSC, 2 x 10 min. 
at room temperature rocking; 2X SSC, 2 x 15 min. at 68° C rocking; 1X SSC, 2 x 15 min. at 68° 
C rocking; 0.1X SSC, 2 x 30 min at 68° C rocking. Sections were equilibrated in a maleic acid 
buffer (MAB; 100 mM maleic acid, 150 mM NaCl, pH 7.5) 2 x 10 min. at room temperature, 
then serum-blocked (2% blocking reagent [B. Mannheim, #1 096 176], 5% lamb serum [Sigma, 
#S4877], in MAB buffer) for 30 min. at room temperature. Alkaline-phosphatase-conjugated 
sheep anti-digoxigenin Fab fragments (Roche, #11093274910) were used as secondary antibody 
at a concentration of 1:500 in blocking buffer. Sections were incubated in secondary antibody for 
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2 hours at room temperature, rocking, then washed 2 x 5 min. in PBS. Sections were incubated 2 
x 5 min. in staining buffer (100 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl2, 0.1% Tween-20, 
pH 9.5) at room temperature, rocking. Staining was performed by incubating sections in BM 
Purple (Roche, #11442074001) at room temperature in the dark rocking for 12 hours.  
Following overnight staining, sections were rinsed three times in PBS then washed 3 x 10 
min. in PBS. Sections were mounted onto gelatin-coated Superfrost Plus slides (Fisher) and 
allowed to dry overnight in the dark. Sections were dehydrated through graded ethanols, cleared 
in Histoclear (National Diagnostics, #HS-200), and coverslipped in Histomount (National 
Diagnostics, #HS-103). 
2.3.8 Immunohistochemistry (IHC) on Human Substantia Nigra (SN) Tissue 
Slides containing cryostat-cut, paraffin-embedded human SN sections were obtained 
from the University of Pittsburgh brain bank in accordance with institutional regulations. Prior to 
staining, sections were de-paraffinized as follows: 60°C x 30 min., 3 x 4 min. Histo-Clear 
(National Diagnostics, #HS-200), 2 x 4 min. 100% ethanol, 2 x 4 min. 95% ethanol, 1 x 4 min. 
70% ethanol, 1 x 5 min. water. Blocking of endogenous peroxidases was performed in 3% H2O2 
for 10 min. at room temperature, followed by a 5-min. wash in water. Heat-mediated antigen 
retrieval was conducted by incubating sections in a citrate buffer (10 mM sodium citrate, 0.05% 
Tween-20, pH 6.0) at 95-100° C for 20 min. Sections were allowed to cool at room temperature 
for 5 min. then washed 3-min. in water. Serum block was performed in 10% NDS in PBS 
containing 0.3% Triton-X (PBST) for 1 hour. Primary antibody (polyclonal goat anti-human 
GATA2, R&D Systems, #AF2046) was resuspended in 1% NDS in PBST at a concentration of 
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1:100, and sections were incubated overnight at 4° C. Primary antibody solution was then re-
applied to the sections the following day for 2 hours at room temperature. After 3 x 10 min. 
washes in PBS, sections were incubated for 1 hour in a solution containing biotin-conjugated 
donkey-anti-goat secondary antibody at 1:200 (Jackson Immunoresearch, #705-065-147) in 1% 
NDS in PBST. After 3 x 10 min. washes in PBS, sections were incubated in ABC peroxidase kit 
solution (Vectastain, #PK-6100) for 1 hour then washed 3 x 10 min. washes in PBS. 
Chromogenic development using Vector VIP chromogen (Vector Laboratories, #SK-4600) was 
carried out according to manufacturer’s instructions. Sections were dehydrated through graded 
ethanols, cleared in Histoclear (National Diagnostics, #HS-200), and coverslipped in Histomount 
(National Diagnostics, #HS-103). 
2.4 RESULTS 
2.4.1 GATA2 positively regulates SNCA in the human dopaminergic neural cell line SH-
SY5Y 
To confirm that GATA2 positively regulates SNCA, as described by Scherzer and colleagues 
(Scherzer et al., 2008), we sought first to reproduce their findings in the same human 
dopaminergic neural cell line they used, using the same methods. If GATA2 positively regulates 
SNCA under basal conditions, then silencing GATA2 expression should lead to consequent 
down-regulation of SNCA expression. Transfection of SH-SY5Y cells with small interfering 
RNA (siRNA) against human GATA2 (siGATA2) for 48 hours led to a significant and dose-
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dependent decrease in GATA2 mRNA relative to a non-targeting siRNA control (siNeg), as 
assessed by RT-QPCR (data not shown). Based on this dose-response curve, an siRNA 
concentration of 120 nM was selected for subsequent experiments. 
 
 
 
 
Figure 1. GATA2 positively regulates transcription of SNCA in SH-SY5Y cells 
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(A) GATA2 mRNA levels are reduced after 48-hour transfection of SH-SY5Y cells with siRNA 
against GATA2 as compared to negative control siRNA (siNeg) (p < 0.01). (B) SNCA mRNA 
levels are reduced by 14% and (C) NEFL mRNA levels are unchanged. GAPDH was used as a 
normalization control to calculate fold-change in mRNA levels. At least 5 independent 
experiments were performed. α=0.05. 
 
 
 
At this concentration, GATA2 message was decreased by about 50% (Figure 1a). In turn, 
GATA2 silencing resulted in a significant (14%) down-regulation of SNCA mRNA, which is 
consistent with the report by Scherzer and colleagues (Figure 1b) (Scherzer et al., 2008). 
Importantly, mRNA levels of neurofilament light chain (NEFL)—a gene that contains no GATA 
elements and thus serves as a negative control—were unchanged following GATA2 knock-
down, indicating that the decrease in SNCA mRNA is due to the loss of GATA2 rather than off-
target effects related to the concentration of siRNA (Figure 1c). 
To determine whether the down-regulation of SNCA observed at the mRNA level is also 
present at the protein level, we performed immunocytochemistry (ICC) for GATA2 and alpha-
synuclein (a-syn) and quantified fluorescence intensity by confocal microscopy. We found that 
GATA2 silencing led to a significant reduction in a-syn protein levels (~60%) (Figure 2). This 
finding is again consistent both in direction and magnitude of a-syn protein reduction with what 
Scherzer and colleagues found by ELISA under the same cell culture conditions (Scherzer et al., 
2008).  
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Taken together, these data confirm the results of Scherzer and colleagues, demonstrating 
that GATA2 is a positive transcriptional regulator of SNCA in the human dopaminergic neuronal 
cell line, SH-SY5Y. 
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Figure 2. GATA2 silencing leads to significant down-regulation of SNCA at the protein level 
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Cells were transfected for 48 hours with either negative control siRNA (siNeg) or siRNA against 
human GATA2 (siGATA2). Cells were fixed, ICC was performed, and fluorescence intensity 
corresponding to protein levels was quantified for GATA2 and a-syn. (A) Representative 
confocal images of cells transfected with siNeg or siGATA2 and stained for GATA2 (green) or 
a-syn (red). Arrow indicates a cell presumably transfected with siGATA2 and showing lower 
GATA2 expression relative to non-transduced cells or cells transduced with siNeg. (B) GATA2 
protein levels are reduced by 76% after 48 hours transfection with siGATA2 as compared to 
siNeg (p < 0.0001). Alpha-synuclein protein levels are reduced by 56% after 48 hours 
transfection with siGATA2 as compared to siNeg (p < 0.0001). Three coverslips from one 
experiment were analyzed. α=0.05.  
2.4.2 GATA2 positively regulates SNCA in the rat dopaminergic cell line PC12 
The overarching goal of this dissertation project is to test the hypothesis that GATA2 positively 
regulates SNCA in vivo, using rat as a model. Therefore, it is important to determine whether the 
GATA element that GATA2 employs to regulate SNCA in human cells is conserved in rat. 
Although the human SNCA locus contains 10 GATA elements, endogenous GATA transcription 
factors occupy only a single GATA element in intron 1 (Scherzer et al., 2008). Alignment of the 
human and rat SNCA intron 1 sequences reveals that this element is in fact well-conserved 
between these species, supporting the possibility that this mode of regulation is likewise 
conserved between these species (Figure 3). 
 
 
  53 
Figure 3. A GATA element in intron 1 of SNCA is conserved between human and rat 
 
 
 
Human and rat SNCA intron 1 genomic DNA sequences were obtained from Ensembl Genome 
Browser (www.ensembl.org/) and aligned using CLC Main Workbench 6. A conserved GATA 
element was found spanning bases 588-591, as indicated by the black bar beneath the sequence 
logo. 
 
 
 
In order to determine whether GATA2 also positively regulates SNCA in rat cells, we 
silenced GATA2 in the rat dopaminergic cell line, PC12, and assessed mRNA levels of SNCA by 
RT-QPCR. An siRNA was designed to recognize a unique region of GATA2 mRNA and thereby 
to silence rat GATA2 specifically (see Section 3.3.2). Transfection of PC12 cells for 48 hours 
with this siRNA (siGATA2) led to a significant and robust decrease in GATA2 mRNA levels 
relative to a non-targeting negative control siRNA (siNeg), as assessed by RT-QPCR (Figure 
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4a). This decrease in GATA2 expression was accompanied by a significant down-regulation in 
SNCA (by 18%), indicating that GATA2 positively regulates SNCA in rat dopaminergic cells in 
addition to human dopaminergic cells (Figure 4b). 
 
 
 
Figure 4. GATA2 silencing leads to down-regulation of SNCA mRNA in a rat dopaminergic cell line 
 
 
 
 (A) GATA2 mRNA levels are reduced by 66% in PC12 cells after 48 hours transfection with 
either negative control siRNA (siNeg) or siRNA against human GATA2 (siGATA2) (p < 
0.0001). (B) SNCA mRNA levels are reduced by 18% in PC12 cells following 48 hours of 
GATA2 silencing (p < 0.05). Means from three independent experiments were compared by 
unpaired, two-tailed Student’s t-test (α=0.05). 
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2.4.3 GATA2 is expressed in adult rat and human substantia nigra pars compacta 
dopaminergic neurons 
The relevance of GATA2 to PD is supported by in vitro data demonstrating that GATA2 
regulates SNCA (Scherzer et al., 2008). Furthermore, it has been shown that GATA2 mRNA and 
protein are detectable in homogenates from human brain regions that undergo degeneration in 
PD, though these experiments did not localize expression to specific cell types (Scherzer et al., 
2008). Work in rodents has demonstrated that GATA2 is expressed within midbrain and 
hindbrain neurons at embryonic and early postnatal ages (Kala et al., 2009; Nardelli et al., 1999; 
Nozawa et al., 2009; Willett & Greene, 2011), and one study has shown the presence of GATA2 
mRNA in laser capture microdissected SNc dopaminergic neurons from adult rat (Richter et al., 
2009). However, a more thorough assessment of GATA2 expression within the adult rat SNc and 
human SNc has not yet been performed. 
We conducted a survey of GATA2 mRNA expression in adult rat midbrain using in situ 
hybridization (ISH) as a first step toward understanding whether GATA2 is expressed in PD-
relevant cell populations. As shown in Figure 5, GATA2 mRNA is present in various midbrain 
nuclei in the adult rat, including: zona incerta (5a’), subthalamic nucleus (5a”), ventral tegmental 
nucleus (5b’), substantia nigra pars reticulata (5b”), periaqueductal gray (5c’), red nucleus (5c”), 
superior colliculus (5d’), medial geniculate nucleus (5d”). Importantly, GATA2 is expressed in 
SNc (Figure 6a-b). 
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Figure 5. GATA2 mRNA is present in various midbrain nuclei in the adult rat 
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(A-D) ISH on coronal adult rat brain sections from approximately -4.338 mm Bregma (A) to -
6.480 mm Bregma (D) demonstrates GATA2 expression in many midbrain nuclei: zona incerta 
(ZI), subthalamic nucleus (STN), ventral tegmental nucleus (VTA), substantia nigra pars 
reticulata (SNr), periaqueductal gray (PAG), red nucleus (RN), superior colliculus (SC), medial 
geniculate nucleus (MGN). (E) ISH using a sense cRNA probe produces no staining, indicating 
specificity of the antisense probe for GATA2 mRNA. The section used as a negative control in 
(E) is anatomically equivalent to (A), i.e. approximately -4.338 mm (Bregma). 
 
 
 
 
Figure 6. GATA2 is expressed in dopaminergic and non-dopaminergic neurons of the rat and human 
SNc 
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(A) In situ hybridization for GATA2 (purple) on adult midbrain sections demonstrates 
expression of GATA2 in various midbrain structures. (B) Higher magnification view of ISH 
from (A) demonstrates GATA2 expression within SNc and SNr neurons.  (C-D) In human SN 
sections, IHC for GATA2 (purple) reveals GATA2 expression in both cells containing 
neuromelanin (i.e. dopaminergic neurons; brown) and cells without neuromelanin (i.e. non-
dopaminergic neurons). (E) Western blot using total protein lysate from the human dopaminergic 
neuronal cell line SH-SY5Y shows that the GATA2 antibody used in (C) and (D) specifically 
recognizes a single band at the expected migration of GATA2. 
 
 
 
Staining of human SN with a specific antibody that was raised against full-length 
recombinant human GATA2 protein revealed GATA2 expression in neuronal profiles containing 
neuromelanin as well as neuronal profiles without neuromelanin (Figure 6c-d). This finding 
indicates that the same cellular distribution of GATA2 expression within the SN is found in rats 
and humans. Importantly, the antibody used recognizes a single band at the predicted molecular 
weight of GATA2 (Figure 6e). 
In summary, GATA2 mRNA is expressed in many nuclei of the adult rat midbrain, 
including the SNc, which is susceptible to degeneration in PD. Within the human SNc, GATA2 
is expressed in both neuromelanin-containing (i.e. dopaminergic) and neuromelanin-lacking (i.e. 
non-dopaminergic) cells. Taken together, these results strengthen the idea that GATA2 may play 
a role in regulating SNCA within PD-relevant cell populations and validate the rat as a suitable 
model of in vivo investigations into GATA2 function in the SNc. 
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2.5 DISCUSSION 
A potential role for GATA transcription factors in PD was suggested by Scherzer and colleagues, 
who performed in vitro studies demonstrating the ability of GATA2 to regulate SNCA expression 
in a human dopaminergic neuronal cell line (Scherzer et al., 2008). In this chapter, we have 
confirmed the results of Scherzer and colleagues, showing that GATA2 positively regulates 
SNCA in the human dopaminergic neuronal cell line, SH-SY5Y (Figures 1-2). The over-arching 
goal of this dissertation project is to test the hypothesis that regulation of SNCA by GATA2 
occurs in vivo in relevant neuronal populations using the adult rat as a mammalian model system. 
Therefore, we first sought to determine whether GATA2 positively regulates SNCA in a rat cell 
line. Given that only one of the 10 GATA elements present in the human SNCA locus is 
functional under basal conditions in SH-SY5Y, it was important to determine whether this 
GATA element is conserved in rat SNCA. The chromatin immunoprecipitation approach that 
Scherzer and colleagues used to determine GATA factor occupancy at human SNCA localized 
the GATA element within intron 1 (Scherzer et al., 2008). By aligning human and rat SNCA 
intron 1 sequences, we found complete conservation of a GATA element at position 588 (relative 
to human SNCA) in intron 1 (Figure 3). Furthermore, we found that silencing GATA2 in the rat 
dopaminergic cell line PC12 led to the expected down-regulation of SNCA, indicating that the 
positive regulation that GATA2 exerts on SNCA expression is conserved between rat and 
human. This finding not only strengthens the idea that regulation of SNCA by GATA2 is 
biologically relevant – i.e. it is a mode of regulation worthy of evolutionary conservation – but 
also provides a rationale for using the adult rat as a model system for further studies in vivo. 
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In an attempt to examine the relevance of GATA2 to PD, we asked whether GATA2 is 
expressed in neurons in the SNc, a brain region that pathologically accumulates a-syn and 
undergoes degeneration in PD. Initial attempts to localize GATA2 protein to rat SNc and cortical 
neurons were fraught with antibody non-specificity issues, rendering the resulting staining 
uninterpretable (data not shown; see section 4.5.3). To circumvent this antibody issue, we used in 
situ hybridization (ISH) to evaluate the expression pattern of GATA2 mRNA. We found that 
GATA2 is expressed in various adult rat midbrain nuclei, including the SNc (Figure 5, 6a-b). 
These findings are consistent with reports showing GATA2 expression in embryonic and early 
post-natal midbrain structures, wherein GATA2 appears to act as a selector gene for GABAergic 
phenotype in post-mitotic neurons within the ventral midbrain (Kala et al., 2009) and neuronal 
migration and maturation in the superior colliculus (Willett & Greene, 2011). 
For GATA2 to be most directly relevant to nigrostriatal degeneration in PD, it is 
necessary to show that it is expressed in SNc dopaminergic neurons. Immunohistochemistry 
(IHC) on human (non-PD) SNc sections revealed that GATA2 is expressed in neurons 
containing neuromelanin (a surrogate marker for dopaminergic neurons). Notably, GATA2 is 
also expressed in non-dopaminergic neurons, likely GABAergic neurons; this finding is 
consistent with previous reports in early post-natal animals (Kala et al., 2009; Willett & Greene, 
2011). 
What role GATA2 may be playing in SNc dopaminergic neurons is unclear. Genome-
wide analysis of GATA2-regulated genes has been undertaken in erythroid cells and epithelial 
cells in vitro (T. Fujiwara et al., 2009; Kang et al., 2012; Linnemann et al., 2011). When the 
authors compared GATA2 chromatin occupancy in primary human umbilical vein endothelial 
cells (HUVEC) versus the human erythroleukemia K562 cell line, they found that only 11-15% 
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of the occupied GATA elements overlapped between the cell types (Linnemann et al., 2011). 
This striking divergence in the majority of presumed GATA2 target genes suggests that the role 
that GATA2 plays can vary markedly by cell type. Therefore, it is difficult to predict what the 
function of GATA2 is in SNc dopaminergic neurons. To examine this issue, the in vivo 
experiments described in Chapter 4 assess whether GATA2 regulates transcription of SNCA in 
nigral neurons of the intact rat. 
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3.0  DESIGN, CLONING & CHARACTERIZATION OF VIRAL VECTORS FOR 
SILENCING GATA2 IN VIVO 
3.1 ABSTRACT 
In Chapter 2, we demonstrated that GATA2 positively regulates SNCA in vitro by silencing 
GATA2 and assessing SNCA levels. Silencing a given gene in brain poses delivery issues that are 
not encountered in vitro, such as blood-brain barrier impermeability and the many systems that 
can degrade exogenous nucleic acids. Viral-mediated gene delivery overcomes these issues and 
is therefore a useful means of modulating gene expression in vivo. In this chapter, we describe 
the design, cloning, and in vitro validation of viral vectors for the specific silencing of rat GATA2 
in rat SNc dopaminergic neurons. These vectors are used in Chapter 4 to test the two hypotheses 
of this dissertation project in vivo (section 1.4). 
3.2 INTRODUCTION 
One of the over-arching goals of this dissertation project is to test the hypothesis that GATA2 
regulates SNCA in vivo. Based on the results of Chapter 2, the adult rat is an appropriate model 
for in vivo investigations into GATA2 function in brain since GATA2 regulation of SNCA in cell 
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lines and cellular distribution of GATA2 expression are conserved in rat (Figures 4,6). In order to 
test the hypothesis that GATA2 regulates SNCA in rat SNc, we decided to use viral-mediated 
gene delivery of short-hairpin RNA (shRNA) to silence GATA2 expression within the rat SNc, 
then assess whether SNCA expression is consequently down-regulated.  
Experiments in Chapter 2 utilized small-interfering RNA (siRNA) to show that GATA2 
positively regulates SNCA in vitro. siRNA is a convenient tool for modulating expression of 
specific genes in vitro, but its utility for in vivo application is limited because of its propensity to 
degrade (Dykxhoorn, Novina, & Sharp, 2003). siRNA is generated intracellularly from shRNA 
upon enzymatic cleavage of the characteristic shRNA hairpin (Dykxhoorn et al., 2003). 
Subsequent incorporation of the siRNA into the RNA-inducing silencing complex (RISC) allows 
for targeted degradation of mRNA. shRNA is more suitable for in vivo applications since it can 
be expressed from plasmids and become siRNA intracellularly; these plasmids can be packaged 
into viral vectors and thereby protected from degradation en route to their cellular site of action. 
An additional advantage of plasmid-based RNA interference is that other cassettes – e.g. one 
expressing a GFP reporter gene under the control of a CMV promoter – can be introduced into 
the plasmid and co-expressed with the shRNA. Figure 7 provides an overview of our 
experimental approach in developing a viral vector for silencing GATA2 in rat SNc. 
This chapter shows the rational design and in vitro validation of siRNAs for silencing rat 
GATA2, and hence describes the production of the viral vectors that will be used for the in vivo 
experiments in Chapter 4. Our results from this chapter set the stage for in vivo modulation of rat 
GATA2 expression by demonstrating that the viral vector we generated robustly and specifically 
silences rat GATA2 in vitro and expresses the reporter gene GFP, which will aid in assessing 
transduction efficiency in vivo. 
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Figure 7. Schematic for design, cloning, and viral packaging of plasmids expressing shRNA against 
rat GATA2 or negative control shRNA 
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This process involved: (1) designing custom siRNAs to unique regions of rat GATA2 transcript 
(see also Figure 8), (2) characterizing their ability to silence rat GATA2 in vitro both robustly and 
specifically, (3) designing a double-stranded oligodeoxyribonucleotide for eventual expression of 
shRNA based on the sequence of the siRNA sequence that showed strong and specific silencing 
of rat GATA2, (4) cloning the double-stranded oligodeoxyribonucleotide into an adeno-
associated virus serotype 2 (AAV2) packaging plasmid, (5) characterizing the ability of the 
plasmid-expressed shRNA to silence rat GATA2 robustly and specifically in vitro, (6) scaling up 
plasmid production, (7) packaging the purified plasmid into AAV2, and lastly (8) characterizing 
the ability of the viral vector to silence rat GATA2 robustly and specifically in vitro. A viral 
vector containing a plasmid that expresses a non-targeting (universal negative control) shRNA 
was engineered using the same methods. ITR, inverted terminal repeat. 
 
 
 
 
3.3 MATERIALS & METHODS 
3.3.1 Cell culture 
Cell culture reagents were purchased from the companies listed in 2.3.1. Undifferentiated PC12 
cells (passage #8-12; ATCC, #CRL-1721) were grown on dishes coated with mouse collagen IV 
(Trevigen, #3410-010-01), and cultured in DMEM growth media containing 5% FBS, 5% horse 
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serum, pencillin (100 units/mL), and streptomycin (100 μg/mL). Cells were grown at 37° C in 
5% CO2 and growth media was replaced every three days. For in vitro viral transduction 
experiments, PC12 cells were differentiated with a 6-day treatment of 100 μg/mL nerve growth 
factor (NGF, BD Biosciences) in DMEM medium containing 1% FBS, 1% horse serum, 
pencillin (100 units/mL), and streptomycin (100 μg/mL). Media changes were performed every 
three days. 
3.3.2 siRNA design, cloning & viral packaging 
Design of siRNA was based on rat GATA2 mRNA sequence (NM_033442.1). This sequence 
was imputed into siRNA design software on the Ambion website 
(http://www.invitrogen.com/site/us/en/home/brands/ambion.html) and a BLAST search was used 
with candidate siRNA sequences to assess alignment to the rat GATA2 mRNA sequence as well 
as homology to other mRNA in the rat transcriptome. Table 1 contains the sequences of the three 
custom rat GATA2 Block-iT 21-mer siRNA duplexes and the negative control siRNA (siNeg) 
that were ordered from Invitrogen, as well as the custom double-stranded 
oligodeoxyribonucleotides that were subsequently ordered from Invitrogen (Table 1).  
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Table 1. Sequences of custom siRNA and shRNA oligodeoxyribonucleotides (5'-3').  
siRNA 
duplexes 
Sequence 
si1077 AGACAGUGACACUUGAUACUU 
 GUAUCAAGUGUCACUGUCUUU 
si1678 UGCUUUGAGGAGCUAUCCAUU 
 UGGAUAGCUCCUCAAAGCAUU 
si2034 UCCUCCAAGGAGAGGUGGCUU 
 GCCACCUCUCCUUGGAGGAUU 
siNeg AAUUCUCCGAACGUGUCACGU 
 CGUGACACGUUCGGAGAAUUU 
shRNA 
oligodeoxyribonucleotides 
Sequence 
sh1678 
GCGGATCCAAAAAATGCTTTGAGGAGCTATCC
AATCTCTTGAATTGGATAGCTCCTCAAAGCATTGAAT
TCGC 
shNeg 
GCGAATTCAAAAAATTCTCCGAACGTGTCACG
TTCTCTTGAAACGTGACACGTTCGGAGAATTGGGGAT
CCGC 
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The AAV2 packaging plasmid was obtained from Bing Wang (University of Pittsburgh) 
(see Appendix for vector map). For directional cloning of the double-stranded 
oligodeoxyribonucleotide into the AAV2 packaging plasmid, BamHI and EcoRI restriction 
enzymes were used according to manufacturer’s instructions (New England Biolabs). Following 
transformation of DH5-alpha chemically-competent E. coli (Invitrogen) with the recombinant 
plasmid, plasmids were purified using a QIAprep MiniPrep kit (Qiagen) and sequenced to 
confirm presence and fidelity of all cassette elements. Scaling up of purified plasmid and further 
purification was performed using an endotoxin-free QIAprep MegaPrep kit (Qiagen). Packaging 
of purified plasmid into AAV2 was performed and quality-controlled by Penn Vector Core 
(Philadelphia, PA). Viruses were diluted to 2 x 1012 GC/mL in sterile PBS and stored at -80° C 
until use. 
3.3.3 Transfection & Transduction in vitro 
Transfection of undifferentiated PC12 cells with custom siRNAs was performed as described in 
2.3.2. Transfection efficiency for siRNA experiments was estimated by transfecting cells with a 
Block-iT fluorescent control probe (Invitrogen) and counting the average percentage of 
fluorescent cells per 20X field using a total of 4 fields per condition. Transfection of 
undifferentiated PC12 cells with shRNA plasmids was done using an Amaxa cell line 
nucleofector kit V (Lonza). 
For viral transduction experiments, undifferentiated PC12 cells (passage #8-12) were 
seeded onto 6-well plates at a cell density of 1.2 x 106 cells/well. The following day, cells were 
differentiated with NGF for 6 days, as described in 3.3.1. Multiplicity of infection (MOI) 
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calculations for viral transduction experiments were made assuming a 1% infectivity of AAV2 
for PC12. Cell media was removed and replaced with warm media containing either AAV2 
expressing shRNA against GATA2 (AAV2.shGATA2.GFP) or AAV2 expressing negative 
control shRNA (AAV2.shNeg.GFP) at the indicated MOI. After three days, media was removed 
and replaced with maintenance media (no virus) for four more days. 
3.3.4 Western blot analysis 
Cells were trypsinized and gently pelleted, then lysed in ice-cold RIPA buffer (Sigma) 
containing a protease inhibitor cocktail (Sigma). Lysates were incubated in lysis buffer on ice for 
10 min., then spun at 10,000 x g for 15 min. at 4° C. A DC protein assay (BioRad) was 
performed on the supernatant to determine protein concentration. Twenty μg protein were 
resuspended in NuPAGE LDS sample loading buffer (Invitrogen) in the presence of NuPAGE 
sample reducing agent (Invitrogen) and heated to 100° C for 3 min. Samples were iced and spun 
briefly, then loaded in onto 4-12% bis-tris polyacrylamide gels (Invitrogen) and run in MOPS 
running buffer (Invitrogen) for 50 min. at 200 V (constant). Gels were transferred to primed 
Immbobilon PVDF-FL membrane (Millipore) at 25 mA (constant) overnight in transfer buffer 
(39 mM glycine, 48 mM Tris base, 0.037% SDS, 20% methanol). Following transfer, the 
membrane was blocked by brief incubations in 100% methanol, water, and then Odyssey 
blocking buffer (LI-COR) for 1.5 hours. Primary antibody incubations were carried out in 
Odyssey blocking buffer at 4° C overnight using the following primary antibodies: goat anti-
human GATA2 polyclonal antibody (R&D Systems, #AF2046; 1:2000), rabbit anti-human 
GATA3 polyclonal antibody (Abcam, #ab32858; 1:500), mouse anti-actin monoclonal antibody 
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(Millipore, #MAB1501; 1:20,000), mouse anti-GFP monoclonal antibody (Millipore, 
#MAB3580; 1:3,000). Following primary antibody incubation, membranes were washed 3 x 10 
min. in PBS, then incubated for 45 min. in Odyssey blocking buffer (LI-COR) containing the 
corresponding infrared fluorophore-conjugated secondary antibody at a concentration of 
1:10,000 in the dark. The following secondary antibodies (all from LI-COR) were used: IRDye 
680-conjugated donkey anti-goat IgG, IRDye 800-conjugated donkey anti-rabbit IgG, IRDye 
800-conjugated donkey anti-mouse IgG. Membranes were washed 3 x 10 min. in PBS in the 
dark, then imaged on an Odyssey scanner (LI-COR).  
For each experiment, conditions were performed in triplicate wells. Band fluorimetry was 
performed using Odyssesy software (LI-COR), and GATA2 or GATA3 bands were normalized 
to their respective beta-actin loading controls. The average of the three triplicate wells was 
calculated and considered an experimental n of one. Depending on the conditions being 
compared, statistical significance was determined by performing either a one-way ANOVA with 
Dunnet post hoc test or an unpaired, two-tail Student’s t-test. α=0.05. 
3.4 RESULTS 
3.4.1 Design and in vitro validation of siRNA for specific silencing of rat GATA2 
The ideal siRNA for silencing rat GATA2 would be one that exclusively recognizes the rat 
GATA2 transcript and nothing else in the rat transcriptome, thereby limiting off-target effects. 
Alignment of rat GATA transcription factor sequences using CLC Workshop 6 software revealed 
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that the highest degree of homology among the GATA transcription factors is found within the 
coding region of these genes, particularly in classical domains such as the two zinc-finger 
domains (Figure 8a-b). Greater sequence divergence among these genes can be found in the 5’ 
and 3’ untranslated regions (UTR). We designed 21-mer siRNAs against three unique regions of 
rat GATA2 mRNA that share little homology with the other five rat GATA transcription factors 
(Figure 8c). Two of these siRNAs (designated si1077 and si1678 for the base pair position where 
they were designed to bind) target sequences within the coding region and one siRNA (si2034) 
targets a sequence in the 3’ UTR. For a negative control siRNA, we used a sequence that has 
been validated through microarray studies not to alter expression of any genes within the rat 
genome (Invitrogen). 
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Figure 8. Rational design of siRNAs for specific silencing of rat GATA2 
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(A) Genomic DNA map of rat GATA2. Vertical boxes represent exons and are denoted by the 
Roman numerals below. Black bars represent intergenic sequences. Colored regions indicate 
coding sequence. (B) mRNA map of rat GATA2. Boxes represent exons and correspond to those 
in (A). White boxes on left and right represent 5’ UTR and 3’ UTR, respectively. Gray arrows 
indicate sites of homology for each of the three siRNAs. (C) siRNA sequences are homologous 
to rat GATA2 mRNA (red sequence) and show sequence divergence from other rat GATA 
transcription factors. Green nucleotides represent mismatches relative to the siRNA sequence. 
 
 
 
To validate the siRNAs for their ability to silence rat GATA2 robustly and specifically, 
we transiently transfected undifferentiated PC12 cells with each of the siRNAs for 48 hours and 
analyzed GATA2 protein levels by western blot (Figure 9). Relative to siNeg, we found that each 
of the siRNAs achieved significant dose-dependent silencing of GATA2 (Figure 9a-b). 
Transfection of cells with a fluorophore-conjugated 21-mer double-stranded RNA probe under 
the same transfection conditions demonstrated a transfection efficiency of 70-80% (data not 
shown). Since si1678 achieved 70-80% GATA2 silencing by western blot, it can be concluded 
that si1678 is maximally efficacious in silencing GATA2. In addition to GATA2, PC12 cells also 
express GATA3, allowing us to assess whether the strong silencing we observed is specific for 
GATA2. Western blots using the same 80 nM siRNA-treated cell lysates as in Figure 9a-b 
showed no significant difference in GATA3 protein levels suggesting that the silencing effect of 
each siRNA is specific to GATA2 (Figure 9c). Since si1678 achieved maximal silencing at lower 
concentrations than si1077 and si2034 and was equally specific for GATA2 (Figure 9b-c), the 
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si1678 sequence was selected as the basis for the subsequent design and cloning of an shRNA-
expressing plasmid (sh1678). 
 
Figure 9. siRNAs robustly and specifically silence rat GATA2 in PC12 cells
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(A) A representative western blot of PC12 cell lysates following 48-hour transfection with 
siRNA against GATA2 shows dose-dependent GATA2 silencing for each of the siRNAs relative 
to siNeg. (B) Quantification of GATA2 silencing from three independent experiments 
demonstrates significant silencing for si1678 at 80 nM and for each of the siRNAs at 160nM. 
Means of si1077, si1678, and si2034 were compared to that of siNeg by one-way ANOVA with 
Dunnet post hoc test (p<0.05). (C) A representative western blot (left) on the 80 nM cell lysates 
used in (A). Quantification (right) of mean GATA3 protein levels from three independent 
experiments shows no significant change in GATA3 protein levels. α = 0.05. 
 
 
3.4.2 Design and in vitro validation of shRNA for specific silencing of rat GATA2 
In order to develop an shRNA-expression vector for in vivo use, it was necessary to construct a 
double-stranded oligodeoxyribonucleotide (oligonucleotide) based on the validated si1678 
sequence that could express shRNA after cloning it into an AAV packaging plasmid. We made 
an oligonucleotide sequence that contained (5’-3’): a BamHI restriction site, the sense si1678 
sequence, a flexible “loop” sequence, the antisense si1678 sequence, and an EcoRI restriction 
site (Figure 7). The rationale behind arranging the sense and antisense si1678 sequences 
separated by a “loop” is to create an shRNA artificially, with the “loop” acting as the hairpin 
(Figure 7). Entering the oligonucleotide sequence into a secondary structure prediction program 
(RNAFold) yielded a prediction of very strong secondary structure, consistent with the formation 
of a hairpin structure (data not shown). The restriction sites flanking the shRNA sequence were 
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chosen so that the oligonucleotide would be in appropriate orientation relative to the U6 
promoter when cloned into the AAV packaging plasmid (see Appendix, 6.0, for vector map). 
Oligonucleotides based on the siNeg sequence were constructed and cloned in the same manner 
to generate a negative control shRNA-expressing plasmid (shNeg). 
Following cloning of the oligonucleotide into the AAV packaging plasmid and plasmid 
purification, we used western blot analysis to test whether sh1678 was able to silence GATA2 
robustly and specifically, similar to what we observed for si1678. Transfection of 
undifferentiated PC12 cells with sh1678 or shNeg for 48 hours resulted in approximately 60% 
transfection efficiency, as detected by expression of the GFP reporter gene from the plasmid 
(Figure 10a-b). Furthermore, significant GATA2 silencing was observed relative to transfection 
with shNeg (Figure 10c-d). Similar to our findings with si1678, no change in GATA3 levels was 
detected (Figure 10e). Taken together, these data indicate that the sh1678 plasmid robustly and 
specifically silences GATA2 and that both sh1678 and shNeg express the GFP reporter gene. 
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Figure 10. sh1678 robustly and specifically silences rat GATA2 in PC12 cells
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(A-B) 48-hour transfection of undifferentiated PC12 cells with sh1678 or shNeg results in 60% 
transfection efficiency (B), as indicated by expression of the reporter gene GFP in green (A). (C) 
Western blot on total cell lysates from undifferentiated PC12 transfected for 48 hours with 
sh1678 or shNeg shows dose-dependent silencing of GATA2 with sh1678 and no significant 
change with shNeg. A representative blot is shown. (D) Quantification of changes in GATA2 
protein levels from three independent experiments using individual Student t-tests to compare 
sh1678 to shNeg at each concentration. (E) Qantification of western blots probed for GATA3 
using the same cell lysates from PC12 transfectants shows no change in GATA3 protein levels (n 
= 3). α = 0.05. 
 
 
 
3.4.3 In vitro validation of viral vectors packaged with shRNA against GATA2 
We selected non-pseudotyped AAV2 as a viral vector for delivery of the sh1678 and shNeg 
plasmids into rat SNc because it was found in vivo to have a strong tropism for rat SNc 
dopaminergic neurons (Cannon et al., n.d.). After scaling up plasmid production and purification, 
we had the sh1678 and shNeg plasmids packaged into AAV2 (hereafter referred to as 
AAV2.sh1678 and AAV2.shNeg). 
As a final step in our in vitro validation, we sought to test whether the AAV2.sh1678 was 
effective in silencing GATA2, similar to si1678 and sh1678. Following viral transduction, it 
typically takes days to weeks to achieve maximal expression levels of transgenes (Dykxhoorn et 
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al., 2003). Since undifferentiated PC12 cells actively divide, a one-week transduction with our 
AAV2 vectors would allow for multiple rounds of cell division to occur, at which point the 
majority of the cells would likely not contain high levels of viral plasmid, thereby 
underestimating silencing effects. To slow cell divison rate, we differentiated PC12 cells for 6 
days with NGF. Six-day differentiation in NGF resulted in extension of processes and a slowing 
of division rate (data not shown). We transduced the differentiated PC12 cells for one week with 
a range of viral titers and found by western blot that both vectors exhibited a dose-dependent 
increase in GFP expression, again indicating that the reporter gene cassette is functional (Figure 
11). Furthermore, we found that transduction of cells with AAV2.sh1678 led to a dose-dependent 
reduction in GATA2 protein levels relative to AAV2.shNeg (Figure 11). Levels of GATA2 
protein did not change across titres of AAV2.shNeg (Figure 11). In summary, both of the viral 
vectors that we generated express the GFP reporter gene – and AAV2.sh1678 strongly silences 
GATA2, whereas AAV2.shNeg has no effect on GATA2 levels. 
 
 
 
 
Figure 11. In vitro validation of viral vectors 
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Transfection of differentiated cells for 1 week with AAV2.sh1678 robustly silences GATA2. 
Both vectors express the reporter gene GFP. 
 
 
 
3.5 DISCUSSION 
Modulation of gene expression in vivo via RNA interference poses several challenges that are not 
encountered when modulating gene expression in vitro. Among these challenges is effective 
targeting of the intact interfering RNA to the cells of interest; this matter is further complicated 
when the cells of interest reside in the brain, which is separated from the systemic vasculature by 
the relatively impermeable blood-brain barrier. In vitro transfection of cells with RNA can be 
accomplished by encasing the RNA in liposomes and adding the RNA-liposome complexes to 
cells (lipofection). Depending on the cell type, the RNA-liposome complexes are often readily 
taken up by the cells. Delivery of RNA to cells in vivo requires first bypassing the many systems 
in place to degrade foreign particles like RNA and liposomes. A common approach to 
circumvent these issues is to perform the gene delivery with a viral vector that preferentially 
infects certain cell types. These vectors can be packaged with the desired gene in the form of a 
plasmid. These vectors still face the challenge of gaining entrance to the brain if infused 
systemically, so the usual approach is to infuse the viral vectors directly into the desired brain 
region. 
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In order to test our hypothesis that GATA2 regulates SNCA in vivo, we decided to create 
a viral vector containing a plasmid that expresses shRNA against rat GATA2 that we could 
infuse directly into the rat brain to silence GATA2 within SNc dopaminergic neurons. We started 
the process of creating this viral vector by selecting unique regions of rat GATA2 mRNA against 
which to design siRNAs. The more specific these regions are to GATA2, the more specific the 
siRNA should be in silencing GATA2, thereby leaving levels of other transcripts – particularly 
the other closely related GATA factors – unchanged. We screened the siRNAs in PC12 cells, 
which express GATA3 in addition to GATA2, and found that they robustly and specifically 
silenced GATA2 while leaving GATA3 levels unaltered (Figure 9). As expected, the shRNA-
expressing plasmid (sh1678) that we developed based on one of the siRNAs (si1678) was 
similarly effective and specific in silencing GATA2 (Figure 10). Additionally, sh1678 and its 
corresponding negative control, shNeg, expressed the GFP reporter gene, which is important for 
localizing transduced neurons in vivo in Chapter 4. Our final validation of the AAV2 virus that 
was packaged with our plasmids demonstrated that these vectors are likewise effective in 
silencing GATA2 in vitro (Figure 11). 
While our data in this chapter validate the viral vectors we have generated for in vivo use, 
it is nonetheless important to note some limitations of our validation studies. We chose to 
examine levels of GATA3 in our validation studies as an indication of specificity. Our rationale 
for this is that GATA3 shares much sequence homology with GATA2 and is therefore more likely 
to be targeted by siRNAs weakly specific for GATA2. Furthermore, GATA3 is the only other 
GATA transcription factor known to be expressed in healthy, post-natal rodent brain. While we 
believe these reasons make it a suitable protein to examine for off-target effects of the 
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siRNA/shRNA/AAV2.shRNA, it is possible (but unlikely) that other transcripts, unrelated to 
GATA2 and GATA3 expression, are influenced by the siRNA.  
It might be suggested that microarray experiments to profile expression changes in large 
numbers of genes following GATA2 silencing in PC12 cells may be a better way to track off-
target effects. However, this approach is confounded by the fact that GATA2 is a known master 
regulator of gene expression; it is expected that modulation of GATA2 expression would bring 
about changes in the expression of many genes. GATA2 has not been shown to directly regulate 
GATA3, so the fact that we are not detecting changes in GATA3 levels upon GATA2 silencing 
supports a lack of siRNA off-target effects. 
Taken together, the data from the rigorous, step-wise characterization of our RNA 
interference reagents in this chapter demonstrate that our viral vectors are appropriate for testing 
the hypothesis in vivo that GATA2 positively regulates SNCA in SNc dopaminergic neurons. 
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4.0  GATA2 SILENCING IN VIVO: CHARACTERIZATION OF EFFECTS ON 
ALPHA-SYNUCLEIN EXPRESSION AND ASSESSMENT OF NEUROPROTECTION 
IN THE ROTENONE RAT MODEL OF PD 
4.1 ABSTRACT 
In this chapter, we directly test the two hypotheses of this dissertation project using the viral 
vectors that we generated in Chapter 3. In order to validate the vectors in vivo, we histologically 
examine their ability to transduce the nigrostriatal system following stereotaxic infusion without 
toxicity per se and silence GATA2. Following validation, we address the first hypothesis – that 
GATA2 regulates SNCA in vivo – by assessing changes in SNCA expression. We address the 
second hypothesis – that silencing GATA2 is protective in the rotenone rat model of PD – by 
delivering the vectors to rats then administering the parkinsonian neurotoxin, rotenone. We find 
that, although GATA2 positively regulates SNCA in SNc neurons, silencing GATA2 does not 
confer neuroprotection against rotenone. 
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4.2 INTRODUCTION 
In this chapter, we validate in vivo the viral vectors that we generated in the previous chapter and 
we use these reagents to test two hypotheses: 1) GATA2 positively regulates SNCA under basal 
conditions in SNc dopaminergic neurons in vivo, and 2) silencing GATA2 expression in SNc 
dopaminergic neurons in vivo is neuroprotective in the rotenone rat model of PD. Since testing 
both of these hypotheses requires modulation of GATA2 expression in a specific subset of 
neurons (SNc dopaminergic neurons), it is important first to ensure that delivery of the viral 
vectors is anatomically accurate, that transgene expression is detectable, and that the 
AAV2.shGATA2 vector silences GATA2 without the viral vectors per se having deleterious 
effects on the nigrostriatal system. Inaccurate delivery or incomplete transgene expression 
(especially from the shRNA cassette) would confound results from experiments assessing SNCA 
expression or neuroprotection since they depend on strong down-regulation of GATA2 
expression in the correct cell population. If the viral vectors per se are harmful the nigrostriatal 
system—e.g. by inducing a dramatic inflammatory response—then they will not warrant further 
testing as potential neurotherapeutic agents. 
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4.3 MATERIALS & METHODS 
4.3.1 Animals 
Twenty-two 7-month old male Lewis rats were purchased from Hilltop Lab Animals, Inc. and 
housed and treated in accordance with National Institutes of Health guidelines and University of 
Pittsburgh Institutional Animal Care and Use Committee (IACUC)-approved protocols. Rats 
were sacrificed and their brains processed for immunohistochemical analysis as described in 
2.3.6. 
4.3.2 Viruses & Stereotaxic surgeries 
shRNA expression cassettes were cloned into an AAV gene transfer plasmid (see Appendix, 6.0, 
for vector map) and were purified, and packaged into AAV2 by Penn Vector Core (Philadelphia, 
PA), as described in 3.3.2. Upon receipt on dry ice, viruses were briefly thawed and diluted in 
sterile PBS to 2 x 1012 GC/mL, which was then quickly prepared into 10 μL aliquots and stored 
at -80° C until use. All viral work was performed in a BSL2+ facility, in accordance with 
approved institutional recombinant DNA and IACUC- protocols. Animals were anesthetized by 
inhalation of 3% isoflurane until unresponsive to painful stimuli, then mounted onto a stereotaxic 
frame and maintained on 1.5 L of oxygen with 2% - 3% isoflurane through a frame-mounted 
nasal cannula. For each infusion, an aliquot of virus was briefly thawed and drawn up in a 
Hamilton syringe (#7635-01) and custom needle (#7803-07; 30-gauge, 1.25-in., 45° bevel), 
placed on the stereotaxic frame and Bregma was measured. For each infusion, 2 μL of virus (at a 
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concentration of 2 x 1012 GC/mL) was delivered over 10 min. (200 nL/min.), and 5 min. were 
allowed to pass before slowly retracting the needle. AAV2.shGATA2 was infused first (-5.5 mm 
A/P, -2.0 mm R/L, -7.5 mm V to bregma), followed by AAV2.shNeg (: -5.5 mm A/P, +2.0 mm 
R/L , -7.5 mm V to bregma). Buprenorphine (0.05 mg/kg, i.p) was administered as a post-
operative analgesic once animals were ambulatory without evidence of labored breathing. 
Animals were monitored daily and buprenorphine was administered at this dose twice per day for 
the first two post-operative days. 
4.3.3 Chromogenic immunohistochemistry (IHC) 
For chromogenic IHC, free-floating sections were removed from cryoprotectant and washed 6 x 
10 min. in phosphate-buffered saline (PBS, pH 7.4). Sections were incubated for 10 min. in 3% 
H2O2 in PBS, then washed 3 x 10 min. in PBS. Sections were blocked in 10% normal donkey 
serum (NDS) in PBS containing 0.3% Triton-X (PBST) for 1 hour. Primary antibody solutions 
were prepared by resuspending the following antibodies (individually) in PBST containing 1% 
NDS: monoclonal mouse anti-GFP antibody (1:4000, Millipore, #MAB3580), polyclonal mouse 
anti-rat CD11b (OX42; 1:150, AbD Serotec, #MCA275G), mouse anti-tyrosine hydroxylase 
(TH; 1:2000; Millipore, #MAB318) Sections were incubated in this solution for 48 hours at 4° C. 
After 3 x 10 min. washes in PBS, sections were incubated for 1 hour in a secondary antibody 
solution containing biotin-conjugated donkey-anti-goat at 1:200 (Jackson Immunoresearch, 
#705-065-147) in 1% NDS in PBST. After 3 x 10 min. washes in PBS, sections were incubated 
in ABC peroxidase kit solution (Vectastain, #PK-6100) for 1 hour then washed 3 x 10 min. 
washes in PBS. Peroxidase development with the DAB chromogen was performed according to 
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manufacturer’s instructions (Vector Laboratories, #SK-4100) then sections were washed 6 x 10 
min. in PBS. Sections were mounted onto Superfrost slides (Fisher) and allowed to dry 
overnight. Lastly, sections were then dehydrated through graded ethanols, cleared in Histoclear 
(National Diagnostics, #HS-200), and coverslipped in Histomount (National Diagnostics, #HS-
103). 
4.3.4 Fluorescent IHC 
Free-floating sections were removed from cryoprotectant and washed 6 x 10 min. in PBS (pH 
7.4). Sections were blocked in 10% NDS in PBST for 1 hour, then incubated in 1% NDS in 
PBST containing one or more of the following primary antibodies: polyclonal goat anti-human 
GATA2 (1:500, R&D Systems, #AF2046); monoclonal mouse anti-GFP antibody (1:4000, 
Millipore, #MAB3580); polyclonal rabbit anti-TH (1:3000, Millipore, #AB152). Primary 
antibody incubation was carried out at 4° C for 48 h. Sections were then washed 3 x 10 min. in 
PBS before incubation in the following secondary antibodies in PBST containing 1% NDS: 
Alexa Fluor 488-conjugated donkey anti-mouse IgG (1:500; Invitrogen), Cy3-conjugated donkey 
anti-rabbit IgG (1:500; JacksonImmuno), Alexa Fluor 647-conjugated donkey anti-goat IgG 
(1:500; Invitrogen). Secondary antibody incubation was carried out at room temperature for 1 h. 
in the dark. Sections were washed in PBS 3 x 10 min. in the dark, mounted onto Superfrost slides 
(Fisher), coverslipped in gelvatol aqueous mounting medium (200 mM Tris-HCl, glycerol, 
polyvinyl alcohol, DABCO, pH 8.2), and dried overnight in the dark. 
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4.3.5 Confocal microscopy & Quantitative fluorescent IHC 
Confocal microscopy and quantification of fluorescent IHC was performed as described in 2.3.5 
with the following modifications. Anatomically-matched SN sections were imaged at 40X using 
the same confocal settings and ROIs were precisely drawn around somata using the confocal 
microscope image analysis software, Fluoview FV1000 (Olympus, Japan). Average fluorescence 
intensity was measured for each ROI and averages and standard errors of the mean (SEM) were 
calculated for each condition. Approximately 100 ROIs were quantified per animal. A paired 
Student’s t-test was used to compare normalized fluorescence intensity means (α=0.05). 
4.3.6 Quantification of striatal TH fluorescence intensity 
Rat striata were immunohistochemically stained for TH using a polyclonal sheep anti-tyrosine 
hydroxylase (TH) antibody (1:2000, Millipore, #AB1542) as described in 4.3.4, except IRDye 
800-conjugated donkey anti-sheep IgG (LI-COR) was used as a secondary antibody at a 
concentration of 1:500 in 1% NDS in PBST. Slides containing stained striata were imaged at 
high resolution on an Odyssey scanner (LI-COR). ROIs were precisely drawn around the TH-
immunoreactive area of the striatum, dorsal to the anterior commissure. Quantification of mean 
fluorescence intensity was performed using Odyssey software (LI-COR) and means were 
compared statistically using a paired Student’s t-test (α=0.05). 
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4.3.7 Western blot analysis 
See section 3.3.4. 
4.3.8 in situ hybridization 
See section 2.3.7 for cloning of GATA2 cRNA probes and ISH. The SNCA cRNA probes were 
cloned as described in (Cannon et al., n.d.). 
4.3.9 Northern blot analysis 
A 7-month old male Lewis rat was deeply anesthetized with CO2 and decapitated in accordance 
with IACUC-approved protocol. The brain was quickly removed and a 15-mg piece of frontal 
cortex was dissected. Total RNA was extracted using an RNeasy mini kit (Qiagen) according to 
manufacturer’s instructions. RNA was checked for sufficient abundance and quality (A260/280 ≥ 
2.00) using a Nanodrop ND-1000 spectrophotometer. Northern blot was carried out under 
RNAse-free conditions. RNA samples were prepared in formaldehyde loading buffer (Ambion) 
with ethidium bromide (0.33 μg/μL/sample), heated at 65° C x 15 min, then loaded onto a 
formaldehyde/MOPS/agarose (1%) gel and run at 60V in NorthernMax denaturing gel buffer 
(Ambion). Running buffer was gently redistributed from cathode to anode every 40 min. 
Transfer to Nytran-N (+) nylon membrane (Schleicher and Schuell BioScience) was performed 
in NorthernMax Transfer Buffer (Ambion) over three hours. The membrane was briefly UV 
cross-linked, then incubated in pre-hybridization buffer (UltraHyb buffer [Ambion], 1 mg/mL 
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Torula RNA [Sigma]). SNCA antisense cRNA probe (see 4.3.8) was added to the pre-
hybridization buffer at a final concentration of 20 ng/mL and incubated overnight at 65° C. The 
membrane was washed serially in 2X SSC, 0.1% SDS then 0.1X SSC, 0.1% SDS and incubated 
in a maleic acid-buffered solution containing alkaline phosphatase-conjugated sheep anti-
digoxigenin secondary antibody Fab fragments (Roche) and blocking reagent. Following 
additional washes, signal was detected by chemiluminescence. 
4.3.10 Rotenone rat study 
Rotenone treatments were performed in accordance with an IACUC-approved protocol. Seven-
month old male Lewis rats were infused with viral vectors as described in 4.3.2. Rotenone 
treatment was performed as described previously (Cannon et al., 2009). Briefly, animals were 
administered rotenone via daily i.p. injection (3.0 mg/kg/d in vehicle containing medium chain 
fatty acids [Miglyol]) until they reached behavioral phenotypic endpoint, at which time they 
were sacrificed as described in 2.3.6. 
4.4 RESULTS 
4.4.1 Stereotactic delivery of AAV2.shGATA2 to rat SN results in strong transduction of 
the nigrostriatal system 
Adeno-associated virus 2 (AAV2) is an attractive vector for in vivo viral gene delivery based on 
its relative tropism for neurons, the duration of its transgene expression, its relative lack of 
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inflammatory response, and its general lack of toxicity (Bowers, Breakefield, & Sena-Esteves, 
2011; Giacca, 2010; Hadaczek, Forsayeth, Mirek, Munson, Bringas, Pivirotto, McBride, 
Davidson, et al., 2009b). AAV2 delivery conditions for transduction of rat SNc dopaminergic 
neurons were optimized previously in our lab (data not shown). Using these conditions, we 
stereotactically infused one SNc with AAV2.shNeg and the other SNc with an equal viral titer of 
AAV2.shGATA2 and waited three or six weeks post-infusion for analysis of transduction. We 
found that a single viral infusion resulted in robust transduction of the SNc, as shown 
immunohistochemically by the presence of the GFP reporter gene throughout much of the 
anterior-posterior axis of the SNc (Figure 12). Transduction was evident in SNc neurons 
spanning from ventromedial SNc to dorsolateral SNc and was approximately equal between the 
side that received AAV2.shGATA2 and the side that received AAV2.shNeg (Figure 12). This 
finding is consistent with the similar transduction efficiency and similar levels of GFP 
expression that we observed with the viruses in vitro (Figures 10-11). 
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Figure 12. GFP staining indicates strong transduction of nigrostriatal cell bodies three weeks after 
stereotaxic delivery of AAV2.shGATA2 and AAV2.shNeg to rat SN 
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(A) Schematic showing anatomical sites of stereotaxic AAV2 infusion. (B) Midbrain sections 
from a representative animal collected three weeks post-infusion and stained 
immunohistochemically for GFP. Sections are aligned anterior to posterior (i-v). Punch holes in 
the dorsal midbrain indicate the SNc that received AAV2.shGATA2. The contralateral SNc 
received an equal titer infusion of AAV2.shNeg. (n=5) 
 
 
 
In order to confirm that the transduced cells are nigrostriatal neurons, we assessed 
whether expression of the reporter gene was also present in terminals within the striatum. As 
shown in Figure 13, GFP expression is detected in terminals throughout the striatum in the same 
animals, indicating anterograde transport of the protein from the site of transduction in the SNc. 
This degree of transduction is consistent with our findings in the SNc (Figure 12). 
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Figure 13. GFP staining of nigrostriatal terminals indicates strong transduction three weeks after 
stereotaxic delivery of AAV2.shGATA2 and AAV2.shNeg to rat SN 
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(A) Schematic showing anatomical sites of stereotaxic AAV2 infusion. (B) Striatal sections from 
a representative animal collected three weeks post-infusion and immunohistochemically stained 
for GFP. Sections are aligned anterior to posterior (i-v). Punch holes in the overlying cortex 
indicate the hemisphere that received AAV2.shGATA2 infusion into SNc. The contralateral SNc 
received an equal titer infusion of AAV2.shNeg. (n=5) 
 
 
 
Because we will eventually test whether GATA2 silencing in SNc dopaminergic neurons 
is neuroprotective in the rotenone rat model of PD, it is important to confirm that transgene 
expression will persist throughout the duration of the rotenone treatment, which is typically one 
to two weeks long for 7-month old rats under this dosing regimen (Cannon et al., 2009). 
Therefore, we performed the same stereotaxic delivery of AAV2.shGATA2 and AAV2.shNeg 
and assessed GFP expression 6 weeks after viral infusion (3 weeks to allow for maximal 
transgene expression and an additional three weeks to extend beyond the longest expected 
rotenone treatment). Consistent with results from our lab and others’ (Cannon et al., n.d.; 
Cederfjäll, Sahin, Kirik, & Björklund, 2012), GFP expression was still present at 6 weeks and 
was overall similar in degree relative to the 3-week animals (Figure 14). GFP expression was 
likewise detected in the striata of these animals, again demonstrating proper transduction of 
nigrostriatal neurons (Figure 15). 
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Figure 14. Strong transgene expression in nigrostriatal cell bodies persists six weeks after stereotaxic 
delivery of AAV2.shGATA2 and AAV2.shNeg to rat SN 
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(A) Schematic showing anatomical sites of stereotaxic AAV2 infusion. (B) Midbrain sections 
from a representative animal collected six weeks post-infusion and immunohistochemically 
stained for GFP. Sections are aligned anterior to posterior (i-v). Punch holes in the dorsal 
midbrain indicate the SNc that received AAV2.shGATA2. The contralateral SNc received an 
equal titer infusion of AAV2.shNeg. (n=6) 
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Figure 15. Strong transduction in nigrostriatal terminals six weeks after stereotaxic delivery of 
AAV2.shGATA2 and AAV2.shNeg to rat SN 
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(A) Schematic showing anatomical sites of stereotaxic AAV2 infusion. (B) Striatal sections from 
a representative animal collected six weeks post-infusion and immunohistochemically stained for 
GFP. Sections are aligned anterior to posterior (i-v). Punch holes in the overlying cortex indicate 
the hemisphere that received AAV2.shGATA2 infusion into SNc. The contralateral SNc 
received an equal titer infusion of AAV2.shNeg. (n=6) 
 
 
 
Taken together, these data demonstrate that stereotaxic delivery of the viral vectors that 
were created and validated in Chapter 3 leads to robust transduction of the rat nigrostriatal 
system and that expression of the transgene persists for at least six weeks. 
4.4.2 Stereotaxic delivery of AAV2.shGATA2 to rat SN produces moderate, transient 
inflammation that does not damage the nigrostriatal system 
One of the limitations of some viral vectors for use in mammalian systems in vivo is their 
propensity to cause an inflammatory response (Giacca, 2010). This response can damage the 
tissue that the vectors are intended to preserve. Although the emergence of AAV as the primary 
type of viral vectors used in many gene therapy trials for neurological disorders is due largely to 
its relatively benign profile with respect to producing inflammatory responses, we nonetheless 
investigated whether AAV2.shGATA2 and AAV2.shNeg produce substantial inflammation. To 
assess inflammation, we stained sections from the animals that were sacrificed at three weeks or 
six weeks post-infusion for the inflammatory marker, OX42 (known alternatively as integrin 
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alpha M [ITGAM], macrophage-1 antigen [Mac-1], complement receptor 3 [CR3], or cluster of 
differentiation 11b [CD11b]). Within the brain, OX42 is expressed selectively on microglia and 
is up-regulated during microglial activation in the context of inflammation (Reid, Perry, 
Andersson, & Gordon, 1993). 
To understand whether stereotaxic delivery per se causes inflammation, we infused PBS 
(equal in volume to our viral deliveries) into one SNc and qualitatively assessed for differences 
between ipsilateral SNc (PBS) and contralateral (no infusion) SNc with respect to OX42 
staining. Ipsilateral OX42 staining was minimal and confined strictly to the needle track (Figure 
16). Otherwise there was no discernable difference in staining between ipsilateral and 
contralateral hemispheres. Furthermore, there was no appreciable difference between the 3-week 
and 6-week cohorts of animals. Taken together, these data indicate that stereotaxic infusion per 
se does not induce inflammation in 7-month old rats at relevant time points for our eventual 
neuroprotection study. 
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Figure 16. Unilateral PBS infusion to rat SN results in little inflammation 
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(A) OX42 immunohistochemical staining on rat midbrain sections (aligned anterior-to-posterior, 
i-v) three weeks after unilateral stereotaxic infusion of PBS demonstrates slight inflammation 
only along the needle track (sections i and ii). (B) OX42 immunohistochemical staining of rat 
midbrain sections (aligned anterior-to-posterior, i-v) six weeks after unilateral stereotaxic 
infusion of PBS demonstrates slight inflammation only along the needle track (section i), similar 
to what was observed in the 3-week cohort.  Punch holes in the dorsal midbrain indicate the SN 
that received AAV2.shGATA2. The contralateral SN received no infusion. (3-week cohort, n=2; 
6-week-cohort, n=2.) 
 
 
 
We used the OX42 staining in the PBS-infused animals as a baseline to assess whether 
infusion of the viral vectors induced inflammation. When we stained midbrain sections from 
animals three weeks after infusion of virus, we found a moderate degree of inflammation relative 
to the 3-week animals that received a unilateral infusion of PBS (Figure 17A). This inflammation 
extends beyond the needle track and appears roughly equal when the ipsilateral 
(AAV2.shGATA2) and contralateral (AAV2.shNeg) hemispheres are compared (Figure 17A). 
Notably, the majority of inflammation is dorsal to the SNc even though the SNc of this 
representative animal was well transduced (Figure 12). Also, we did not detect in any of our 
animals frank necrotic lesions, suggesting the absence of severe inflammation. 
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Figure 17. OX42 staining of rat midbrain sections three weeks and six weeks after AAV2 infusion to 
SN shows moderate but transient inflammation 
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(A) OX42 immunohistochemical staining on rat midbrain sections (aligned anterior-to-posterior, 
i-v) three weeks after bilateral stereotaxic infusion into SN of AAV2.shGATA2 (indicated by 
punch hole in dorsal midbrain) or AAV2.shNeg. Note similar inflammatory response for 
AAV2.shGATA2 and AAV2.shNeg. Also, OX42 staining is stronger and more extensive than 
that which was observed following unilateral PBS infusion to SN (Figure 16A). (B) OX42 
immunohistochemical staining of rat midbrain sections (aligned anterior-to-posterior, i-v) six 
weeks after bilateral stereotaxic infusion into SN of AAV2.shGATA2. Note that OX42 staining 
is barely detectable as compared to OX42 staining at three weeks post-infusion (A). OX42 
staining intensity six weeks post-infusion is instead similar to that which was observed following 
unilateral PBS infusion to SN (Figure 16a-b). (3-week cohort, n=5; 6-week-cohort, n=6.) 
 
 
 
This inflammation appears to resolve by six weeks post-infusion, resulting in a pattern of 
OX42 staining that is similar to that observed in the animals that received unilateral infusion of 
PBS (Figure 17B). Nonetheless, it is important to understand what impact, if any, the observed 
moderate, transient inflammation induced by the viral vectors has on the integrity of the 
nigrostriatal system – i.e. the intended target for neuroprotection in our subsequent studies. To 
this end, we examined whether there was any preferential loss of nigrostriatal terminals in the 
AAV2.shGATA2 versus AAV2.shNeg hemispheres by staining sections for the dopaminergic 
marker, TH. Such loss of terminals is a sensitive marker for damage to the nigrostriatal system 
and is commonly used in parkinsonian models to detect such damage (Cannon et al., 2009; 
Cannon, Sew, Montero, Burton, & Greenamyre, 2011). We did not observe at either time point 
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(three weeks or six weeks post-infusion) a focal lesion in dopaminergic nigrostriatal terminals, 
suggesting that neither vector is toxic (Figure 18 a,c). When we quantitatively compared TH 
fluorescence intensity between the ipsilateral (AAV2.shGATA2) and contralateral 
(AAV2.shNeg) striata and we found no significant difference for either time point cohort, 
suggesting no preferential toxicity of one vector over the other (Figure 18 b,d). Taken together, 
these data suggest that neither vector is toxic to the nigrostriatal system. 
 
 
 
Figure 18. Moderate, transient inflammation induced by viral vectors does not lead to nigrostriatal 
damage 
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(A) Delivery of AAV2 vectors to SN does not lead to loss of nigrostriatal terminals, as indicated 
by the lack of focal lesion observed upon immunohistochemically staining striatal sections for 
TH three or six weeks post-infusion. (B) AAV2.shGATA2 does not alter striatal TH levels three 
or six weeks after infusion into rat SN, as compared to AAV2.shNeg. Statistical comparisons of 
mean striatal TH fluorescence intensity were performed using a paired Student’s t-test. α=0.05. 
 
 
 
4.4.3 GATA2 silencing in rat SN is not detectable by quantitative fluorescent IHC 
We have shown that the viral vectors that were validated in vitro in Chapter 3 yield robust, 
persistent transduction of the rat nigrostriatal system when stereotactically delivered to the SN 
and that delivery of these viral vectors is not associated with chronic inflammation or damage to 
the nigrostriatal system. To confirm that the shRNA cassette in our viral plasmid is functional in 
vivo – i.e., able to silence GATA2 in SNc dopaminergic neurons – we assessed GATA2 protein 
levels by confocal microscopy and fluorescent immunohistochemistry quantification following 
viral transduction. For this purpose, we utilized the same polyclonal antibody that we used for 
our in vitro studies in Chapter 2. This antibody was raised against full-length recombinant human 
GATA2 protein, but given the 93% protein sequence identity between human and rat GATA2 
and the fact that the antibody is polyclonal, it was predicted that the antibody would cross-react 
with rat GATA2 protein. 
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In animals that were sacrificed three weeks after bilateral infusion of AAV2.shGATA2 
and AAV2.shNeg, we found widespread transduction of SNc dopaminergic neurons, as shown in 
the representative images in Figure 19 by the colocalization of TH and GFP (Figure 19a). 
Surprisingly, confocal quantification of immunohistochemical fluorescence intensity 
corresponding to GATA2 protein within TH-positive regions of interest (ROIs) failed to show 
any difference between AAV2.shGATA2 and AAV2.shNeg (Figure 19b). Comparing GATA2 
levels in SNc dopaminergic neurons that had been transduced with AAV2.shGATA2 with 
GATA2 levels in neighboring untransduced dopaminergic neurons within the ipsilateral SNc 
also failed to demonstrate the expected GATA2 silencing (Figure 19c). 
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Figure 19. Confocal imaging and quantification of immunohistochemically stained midbrain sections 
three weeks after AAV2 infusion show no reduction in GATA2 protein levels 
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(A) Representative confocal images of SNc stained for GFP (green), TH (blue), and GATA2 
(red) show a similar degree of transduction between AAV2.Neg-infused SN (top panel) and 
AAV2.shGATA2-infused SN (bottom panel). (B) No significant difference in GATA2 mean 
fluorescence intensity was observed between TH neurons transduced with AAV2.shGATA2 and 
TH neurons transduced with AAV2.shNeg (left). Nor was any significant difference in GATA2 
mean fluorescence intensity observed when comparing TH neurons transduced with 
AAV2.shGATA2 and ipsilateral untransduced TH neurons (right). Statistical comparisons of 
mean GATA2 fluorescence intensity were made using a paired Student’s t-test. α=0.05. (n=5) 
 
 
 
Examination of GATA2 protein levels in the 6-week cohort of animals showed a very 
modest decrease in GATA2 protein levels in the dopaminergic neurons transduced with 
AAV2.shGATA2 versus AAV2.shNeg that reached significance using a paired t-test (normalized 
difference of means = 18%; p = 0.0217) (Figure 20c, left). The magnitude of this effect is in 
striking contrast to the maximal silencing that we had observed in vitro (Figures 9-11). 
Furthermore, we were unable to detect any significant difference in GATA2 protein levels when 
GATA2 mean fluorescence intensity in SNc dopaminergic ROIs was compared to untransduced 
dopaminergic ROIs in the ipsilateral SNc (Figure 20c, right). 
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Figure 20. Confocal imaging and quantification of immunohistochemically stained midbrain sections 
six weeks after AAV2 infusion show no robust reduction in GATA2 protein levels 
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(A) Representative confocal images of SNc stained for GFP (green), TH (blue), and GATA2 
(red). A similar degree of transduction is observed between SN infused with AAV2.Neg (top 
panel) and SN infused with AAV2.shGATA2 (bottom panel). (B) Western blot using the anti-
GATA2 that was used for IHC reveals the presence of a non-specific band using PC12 cell 
lysates. (C) A modest decrease in GATA2 mean fluorescence intensity was detected when 
comparing TH-positive neurons transduced with AAV2.shGATA2 and TH-positive neurons 
transduced with AAV2.shNeg (left). No significant difference in GATA2 mean fluorescence 
intensity when comparing TH neurons transduced with AAV2.shGATA2 and ipsilateral 
untransduced TH neurons (right). Statistical comparisons of mean GATA2 fluorescence intensity 
were made using a paired Student’s t-test. α=0.05. (n=6) 
 
 
 
These immunohistochemical results suggested that the GATA2 antibody might lack 
specificity in rat tissue. Western blot analysis using the same polyclonal anti-human GATA2 
antibody on rat PC12 cell total lysates revealed the presence of a slower-migrating (and more 
immunoreactive) band in addition to the GATA2 band (Figure 20b). This higher molecular 
weight band does not diminish when GATA2 is silenced in vitro, demonstrating that it is not 
related to GATA2 and is therefore non-specific (data not shown). Thus, the failure to detect the 
expected reduction in GATA2 protein levels in SNc dopaminergic neurons by confocal analysis 
is likely because the antibody cross-reacts with another antigen that is present in these cells and 
whose levels are not altered by shGATA2. In support of this hypothesis, the observed staining 
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pattern for this transcription factor was, for the most part, diffusely cytosolic rather than nuclear 
(Figures 19-20). 
Taken together, these data indicate that GATA2 silencing cannot be detected in 
transduced SNc dopaminergic neurons by quantitative confocal analysis of fluorescent 
immunohistochemistry, likely due to antibody non-specificity issues. 
4.4.4 In situ hybridization is a sensitive technique to detect gene silencing in vivo 
We ascribe our inability to detect robust GATA2 silencing by quantitative fluorescent 
immunohistochemistry analysis to antibody non-specificity. Screening of other commercially 
available antibodies as well as two custom antibodies that were raised against peptide sequences 
of rat GATA2 showed these antibodies to be similarly inadequate (data not shown). In an attempt 
to circumvent these antibody issues, we asked whether GATA2 silencing could be detected at the 
mRNA level by in situ hybridization (ISH). 
We developed a complementary RNA (cRNA) probe against the 422-bp coding sequence 
of rat a-syn (SNCA) mRNA (antisense probe) as well as a reverse-complement sequence control 
cRNA probe (sense probe) (Figure 21a). Northern blot analysis on total RNA isolated from rat 
cortex showed a single band corresponding to the migration of SNCA mRNA, indicating that the 
probe is specific for SNCA mRNA (Figure 21b). ISH on midbrain sections from rats that 
received SN infusion of AAV2.shSNCA showed effective silencing of SNCA as compared to the 
contralateral SNc that received an equal-titer infusion of AAV2.shNeg (Figure 21c). As 
expected, no staining was observed with the negative control sense cRNA probe, providing 
further evidence that the antisense probe specifically recognizes SNCA mRNA. These data 
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clearly demonstrate that ISH is a sensitive technique to assess gene silencing in vivo. Therefore, 
we applied a similar strategy to determine whether AAV2.shGATA2 infusion knocks down 
GATA2 message at 3 and 6 weeks post-infusion. 
 
 
Figure 21. Validation of in situ hybridization as a sensitive method for detecting gene silencing in vivo 
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(A) Schematic showing SNCA mRNA and region to which the cRNA probes (gray bar) were 
designed for specific detection of SNCA mRNA. (B) Northern blot on total RNA extracted from 
adult rat cortex shows specific detection of SNCA mRNA. (C) ISH with the antisense SNCA 
cRNA probe performed on midbrain sections from rats three weeks after infusion of viral vector 
engineered to silence SNCA (“shSNCA”) in SN shows robust silencing of SNCA mRNA in SNc 
as compared to the contralateral SN, which received non-targeting negative control (“shNeg”) 
vector. Negative control ISH staining using sense SNCA cRNA probe on adjacent midbrain 
section shows no staining. Images in (C) are representative from three rats that received bilateral 
infusion of AAV2.shSNCA and AAV2.shNeg. (D) Schematic showing GATA2 mRNA and 
region to which the cRNA probes (gray bar) were designed for specific detection of GATA2 
mRNA. Note: SNCA and GATA2 mRNA sizes are not drawn to same scale. 
 
 
 
4.4.5 GATA2 silencing is detectable by in situ hybridization 
For GATA2 ISH we designed antisense and sense cRNA probes against a 399-bp sequence in 
the 3’ UTR, where homology among the six GATA transcription factors (as well as other rat 
transcripts) is lowest (Figure 21d). In contrast to our results with IHC, ISH on midbrain sections 
showed effective GATA2 silencing in the SNc in both the 3-week and 6-week AAV2-infused 
cohorts (Figure 22a). The observed decrease in GATA2 mRNA was not due to cell loss since TH 
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staining was similar in the AAV2.shGATA2- and AAV2.shNeg-infused hemispheres (Figure 
22b). 
4.4.6 GATA2 positively regulates SNCA in vivo 
If GATA2 regulates SNCA under basal conditions in vivo as it does in vitro, then the silencing of 
GATA2 should lead to consequent down-regulation of SNCA. We used the SNCA cRNA probes 
that we generated and validated previously (Figure 21a-c) to determine whether SNCA mRNA 
levels were indeed decreased following GATA2 silencing in SN. At both 3 and 6 weeks post-
transduction with AAV2.shGATA2, there was a striking reduction in SNCA mRNA levels in 
SNc relative to the contralateral SNc, which received AAV2.shNeg (Figure 22c). These data 
therefore demonstrate that GATA2 regulates SNCA in SNc under basal conditions in rat. 
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Figure 22. GATA2 positively regulates SNCA in rat SNc 
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(A) ISH performed using antisense cRNA probe for GATA2 on midbrain sections from rats three 
weeks (left) or six weeks (center) post-infusion of AAV2. No staining is observed when ISH is 
performed on midbrain sections using the corresponding sense cRNA probe (right). Higher 
magnification (10X) images show decrease in GATA2 mRNA in the SNc that received 
AAV2.shGATA2 as compared to the contralateral SNc that received AAV2.shNeg. (B) Staining 
of midbrain sections from these animals for TH shows that decrease in mRNA is not due to loss 
of dopaminergic neurons (10X magnification). (C) ISH performed using the antisense cRNA 
probe for SNCA mRNA on midbrain sections from rats three weeks (left) or six weeks (center) 
after viral infusion shows down-regulation of SNCA in SNc where GATA2 has been silenced 
relative to the contralateral (shNeg) SNc. No staining is observed when ISH is performed on 
midbrain sections using the corresponding sense cRNA probe (right). Higher magnification 
(10X) images show decrease in SNCA mRNA in SNc that received AAV2.shGATA2 as 
compared to contralateral SNc that received AAV2.shNeg. (3-week cohort, n=1; 6-week cohort, 
n=1) 
 
 
 
4.4.7 GATA2 silencing is not neuroprotective in the rotenone rat model of Parkinson’s 
disease 
Systemic rotenone administration to rats produces a behavioral phenotype characterized by 
progressive bradykinesia as well as a pathological phenotype characterized by nigrostriatal 
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degeneration, formation of intracellular proteinaceous aggregates that contain a-syn, and various 
other cellular features similar to PD (Betarbet et al., 2000; Cannon et al., 2009). Importantly, the 
dopaminergic lesion produced by rotenone is bilateral and symmetric (data not shown). In the 
striatum, loss of nigrostriatal terminals can be visualized by immunohistochemical staining for 
TH. Therefore, effects of putative neuroprotective interventions (e.g. viral gene delivery) can be 
compared across hemispheres for their ability to preserve nigrostriatal terminals in rotenone-
treated animals. We utilized this fact in designing an experiment to test the hypothesis that 
GATA2 silencing protects SNc dopaminergic neurons against the cytotoxic effects of rotenone 
(Figure 23). 
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Figure 23. Silencing of GATA2 in SNc dopaminergic neurons is not neuroprotective in the rotenone 
rat model of PD. 
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(A) Schematic showing treatment timeline. (B, left) Weight loss after commencement of daily 
rotenone injections was recorded daily as percentage of initial weight. Animals that received 
AAV2 viral infusions followed by rotenone treatment (AAV2 + Rotenone, n=5) show no 
obvious difference in rate of weight loss as compared to a cohort of animals that received 
rotenone and no viral infusion (Rotenone, n=12). (B, right) Animals in the AAV2 + Rotenone 
cohort show no significant difference in survival as compared to animals in the Rotenone cohort 
(Logrank test, χ2=0.7180, p=0.3968, α=0.05). (C, left) Striatal TH staining on a representative 
animal from the AAV2 + Rotenone cohort shows equal nigrostriatal terminal loss between 
hemispheres, with focal lesions visible in dorsolateral striatum bilaterally. (C, right) 
Quantification of mean striatal TH fluorescence intensity shows no significant difference 
between AAV2.shGATA2 and AAV2.shNeg hemsipheres (paired Student’s t-test, α=0.05). 
 
 
 
Rats received bilateral infusion of viral vectors as before, then were given daily i.p. 
injections of rotenone starting three weeks after infusion until they reached behavioral 
phenotypic endpoint (Figure 23a). There was no significant difference in rate of weight loss or 
survival between the animals that received AAV2 infusions plus rotenone (“AAV2 + Rotenone”) 
and the animals that received rotenone alone (“Rotenone”) (Figure 23b). Comparison of striatal 
TH intensity within the AAV2 + Rotenone cohort revealed no significant side-to-side differences 
(Figure 23c). These findings indicate that GATA2 silencing in SNc dopaminergic neurons does 
not protect against rotenone-induced nigrostriatal degeneration. 
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4.5 DISCUSSION 
The goals of this data chapter were to validate in vivo the viral vectors generated in Chapter 3 
and to determine: (1) whether GATA2 positively regulates SNCA under basal conditions in rat 
SNc dopaminergic neurons, and (2) whether silencing GATA2 in these cells confers protection 
against rotenone, a neurotoxin that models PD in rat. Validation of the viral vectors required 
demonstrating that, when delivered to the rat SNc, they extensively transduce the nigrostriatal 
system and silence GATA2 within SNc dopaminergic neurons without causing damage. Testing 
the two hypotheses required, respectively, silencing GATA2 in rat SNc dopaminergic neurons 
and examining whether SNCA levels are consequently reduced and combining GATA2 silencing 
with rotenone treatment followed by assessment of nigrostriatal pathology. 
4.5.1 Viral transduction of rat SNc is robust 
We demonstrated that transduction of the rat nigrostriatal system with our viral vectors is robust 
and extensive, and results in long-lasting transgene expression (to at least six weeks post-
infusion, which was the latest time point we examined) (Figures 11-15). As expected for this 
neurotropic virus, the vast majority of transduced cells were neurons; within the SN, the majority 
of these neurons were dopaminergic (Figures 19-20). Based on these findings, it can be 
concluded that the delivery of the viral vectors was accurate and likely extensive enough to have 
transduced the majority of SNc dopaminergic neurons, which was a critical prerequisite for 
adequately testing our hypotheses. 
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4.5.2 Delivery of viral vectors causes moderate but transient inflammation in the 
midbrain 
Inflammation is a potentially protective, physiological response to invading pathogens such as 
viruses. However, in the context of gene therapy – where viral vectors are used to deliver 
therapeutic genes – such a reaction can limit the utility of these reagents. Viral-mediated 
induction of inflammation in brain parenchyma is especially important to assess when validating 
gene therapy vectors for PD, where inflammation is thought to exacerbate PD and, possibly, 
contribute to the pathogenesis of disease (Block, Zecca, & Hong, 2007; Glass, Saijo, Winner, 
Marchetto, & Gage, 2010). Some viral vectors are more prone than others to inducing 
inflammation (e.g., adenoviruses, herpes simplex viruses); AAV is among the least immunogenic 
viral vectors (Giacca, 2010). 
In this study, we found that stereotaxic delivery of PBS (the vehicle for the viral vectors) 
did not cause appreciable inflammation (Figure 16); however, we did note moderate – yet 
transient – inflammation in ventral midbrain after delivery of either viral vector (Figure 17). 
Resolution of transient inflammation has been described previously for various viral vectors, 
including AAV2, and is therefore not unexpected. The bilateral experimental design that we 
employed for our in vivo studies – in which each animal serves as its own control by receiving 
infusion of AAV2.shGATA2 into the ipsilateral SNc and AAV2.shNeg into the contralateral 
SNc – allowed us to conclude that the vectors are equivalent in the degree of inflammation they 
instigate. 
Although inflammation can lead to neuronal dysfunction and death, there was no 
evidence of necrotic lesions, which are typical when there is a severe inflammatory response. 
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Nonetheless, we took a further step to ensure that the viral vectors are not harmful to the 
nigrostriatal system by examining whether their delivery to SNc resulted in loss of dopaminergic 
nigrostriatal terminals. We found no focal lesion in either hemisphere, suggesting that neither 
viral vector is toxic to the nigrostriatal system (Figure 18). 
Without comparing striatal TH fluorescence intensity levels in these virus-infused brains 
to uninfused or PBS-infused brains, we cannot conclude that the delivery of these viruses has no 
effect at all on nigrostriatal integrity. From our data, we can only conclude that the 
AAV2.shGATA2 vector does not exert any preferential toxicity as compared to the 
AAV2.shNeg vector. This finding is by itself interesting in that it suggests that GATA2 does not 
regulate genes that are vital to survival of adult SNc neurons. 
Taken together, these findings suggest that the vectors per se are not toxic to the 
nigrostriatal system, and are therefore suitable for testing as potential neurotherapeutic agents in 
the rotenone rat model of PD. 
4.5.3 Detection of GATA2 silencing in vivo 
We were surprised that we were unable to detect GATA2 silencing reliably at the protein level by 
quantitative fluorescent IHC. In the course of troubleshooting this issue, we considered four 
possible confounders: (1) GATA2 antibody non-specificity (most likely), (2) AAV2.shGATA2 
vector does not work in vivo, (3) in vivo turnover of GATA2 protein is very slow, and (4) 
methodological issues with confocal imaging and quantification. 
Validating antibody specificity is critical to ensuring that immunohistochemical 
experiments are of high quality, yet antibodies can be difficult to generate and properly validate 
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for a multitude of reasons. Under conditions of antibody cross-reactivity, reduced levels of 
GATA2 would be “masked” by an extraneous signal from an irrelevant antigen expressed in SNc 
dopaminergic neurons, and would thereby evade detection. The odd sub-cellular staining pattern 
we observed for GATA2 in rat SNc – i.e. a mixture of diffuse and punctate cytoplasmic staining 
with diffuse nuclear staining – was our first indication that our failure to detect GATA2 silencing 
may be confounded by antibody non-specificity. While it is possible for a transcription factor to 
be present in the cytosol under basal conditions and recruited to the nucleus under certain 
circumstances, this phenomenon has not been reported for GATA2. 
The antibody we used for quantifying GATA2 silencing in vivo is an affinity-purified 
polyclonal antibody raised against recombinant, full-length human GATA2 protein. There is 
93% identity between human and rat GATA2 protein sequences so cross-reactivity with the rat 
antigen is probable, but recognition of additional, unintended antigens (non-specificity) based on 
structural or sequence similarity remains a hazard nonetheless. Proteins that share much 
sequence homology are therefore at risk of being co-detected by the same antibody. Such a 
situation can usually be avoided by evaluating the protein sequence against which the antibody 
was raised to all rat proteins for homology with other sequences in the rat proteome using a 
BLAST search. Using only antibodies that meet this criterion of in silico specificity increase the 
likelihood that the antibody will specifically recognize only the intended antigen. As our GATA2 
antibody was raised against the full-length protein, we could not meaningfully use a BLAST 
search to identify proteins likely to cross-react with the antibody. The fact that our GATA2 
antibody is polyclonal also increases the likelihood of cross-reactivity since it is necessarily 
composed of a mix of antibodies that identify various epitopes on the inoculated (full-length 
human GATA2) protein. 
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The gold standard control experiment to demonstrate antibody specificity is to compare 
the observed staining with staining under identical conditions on the same tissue from a knock-
out animal of the same age. Given the general scarcity of knock-out rats and the fact that GATA2 
knock-out mice die at embryonic day 10.5 (Tsai et al., 1994), it was not possible for us to 
validate our GATA2 antibody properly. 
To help test the specificity of our GATA2 antibody in rat, we determined whether the 
antibody recognizes a single band corresponding to the expected migration of GATA2 by 
western blot using rat cell lysates. Antibody cross-reactivity is noted when multiple bands 
(unrelated to the protein of interest) appear. Although the conditions for western blot (i.e. 
linearized proteins coated in SDS) and IHC (i.e. PFA-fixed proteins encased in permeabilized 
cells in situ) differ considerably, observing additional bands by western blot often portends 
antibody non-specificity by IHC. We observed an additional band that was in fact more 
immunoreactive than the GATA2 band by western blot using PC12 cell lysates from our in vitro 
viral transduction experiments (Figure 20b). This band does not decrease when GATA2 is 
silenced, which confirms that it is a non-specific band (data not shown). Therefore, we have 
multiple lines of evidence supporting that antibody non-specificity may be responsible for our 
inability to detect GATA2 silencing at the protein level in vivo.  
A second (less likely) possible explanation for our inability to detect GATA2 silencing at 
the protein level in vivo may be that the shRNA cassette in the plasmid that the viral vector 
delivers does not function properly. Although theoretically possible, this would be surprising 
since the cassette functions optimally in our in vitro validation experiments  (Figures 9-11). To 
rule out this possibility, we re-sequenced the plasmid from virus and found that the sequence was 
correct (data not shown).  
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A third (and similarly unlikely) possibility is that there is a marked difference in the 
kinetics of GATA2 protein turnover in vivo as compared to in vitro. In vitro we detect reduction 
in GATA2 protein levels by 48 hours post-transfection (Figure 2), which is consistent with the 
short half-life that has been reported for GATA2 (approximately 1.5 hours) in vitro in a 
hematopoietic cell line (Minegishi et al., 2005). Differences in half-life may be cell type 
dependent and may indeed differ in vivo, but there is no easy way to explore this possibility 
experimentally. 
The final possibility we considered that could explain our inability to detect robust 
GATA2 silencing at the protein level in vivo is that quantitative fluorescent IHC by confocal 
microscopy is insufficiently sensitive to detect knock-down of GATA2 protein. However, this 
method successfully detected robust silencing in our in vitro studies in Chapter 2 (Figure 2) and 
we have used this technique to show effective silencing of SNCA in rat SNc (Cannon et al., n.d.). 
In conclusion, it is most likely that the GATA2 antibody we used for in vivo detection of 
GATA2 silencing is non-specific. Since our attempts to validate other GATA2 antibodies – both 
commercially available as well as custom antibodies – were unsuccessful, we decided to abandon 
IHC altogether as a method for demonstrating GATA2 silencing in vivo. 
4.5.4 In situ hybridization (ISH) is a sensitive method to detect gene silencing in vivo 
We performed ISH on midbrain tissue from animals transduced with AAV2.shSNCA as a proof 
of principle experiment to show that ISH is a sensitive technique for detection of gene silencing 
in vivo (Figure 21). We applied this technique to tissue from our 3-week and 6-week GATA2 
silencing cohorts and showed robust silencing of GATA2 (Figure 22a). This finding validates that 
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our viral vectors work in vivo and are suitable for testing the two hypotheses that we set out to 
address in this dissertation project. This finding also confirms our suspicion that our inability to 
detect GATA2 silencing at the protein level was due to antibody non-specificity. 
Although no formal behavioral tests were conducted beyond simple observation, it is 
noteworthy that the animals in which GATA2 was unilaterally silenced in SNc dopaminergic 
neurons displayed no gross behavioral phenotype – e.g. unilateral turning or unilateral abnormal 
movements. Consistent with the lack of nigrostriatal pathology that we detected in these animals 
(Figure 18), this finding suggests that GATA2 is not essential to the survival of these cells. 
ISH detection of SNCA mRNA in midbrain sections from the 3- and 6-week GATA2 
silencing cohorts clearly showed that SNCA expression is decreased following GATA2 silencing. 
This demonstrates that GATA2 positively regulates SNCA in SNc dopaminergic neurons in vivo, 
and thereby confirms our first hypothesis. This finding is significant for several reasons. First, it 
is the only in vivo validation to date of a specific trans-acting regulator of SNCA. Second, it 
extends the findings of Scherzer and colleagues (Scherzer et al., 2008) and validates their 
innovative in silico approach to identify putative transcriptional regulators through analysis of 
gene expression databases. Third, the in vivo confirmation that GATA2 regulates SNCA in SNc 
dopaminergic neurons allows for examination of other putative target genes using a similar 
approach on the same tissue – e.g., the heme-metabolism genes that were identified in the in 
silico studies of Scherzer and colleagues (Scherzer et al., 2008). 
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4.5.5 Why isn’t GATA2 silencing neuroprotective in the rotenone rat model of PD? 
Since we have shown that GATA2 regulates SNCA in vivo in SNc dopaminergic neurons, 
GATA2 could theoretically contribute to PD pathogenesis by: (1) being aberrantly up-regulated 
or active such that it induces toxic levels of expression of target genes like SNCA, and/or (2) 
contributing to basal expression of SNCA (and possibly other genes) in a cellular context already 
burdened by excess a-syn. If either case were true, then silencing GATA2 could theoretically be 
therapeutic in PD. To test this hypothesis, we conducted a neuroprotection study in which rats 
received bilateral infusion of viral vectors followed by treatment with rotenone until they 
reached behavioral phenotypic endpoint. We assessed neuroprotection based on the following 
endpoints: rate of weight loss (an indicator of rate of decline), survival (latency to phenotypic 
endpoint), and loss of dopaminergic nigrostriatal terminals (a sensitive indicator of nigrostriatal 
damage). As compared to rats treated with rotenone alone, rats that received the viral vectors 
followed by rotenone did not show any differences in rate of weight loss, survival, or 
dopaminergic nigrostriatal terminal loss (Figure 23b-c). Though there are additional 
neuroprotection endpoints that can be assessed (e.g., stereological cell counting), all three of our 
chosen endpoints demonstrate that silencing GATA2 in SNc dopaminergic neurons is not 
protective in the rotenone rat model of PD, leading us to reject our second hypothesis. 
There are several potential reasons for why GATA2 silencing is not neuroprotective in the 
rotenone rat model of PD. First, it is extremely probable that silencing a gene that is well known 
to function as a master regulator of transcription in other systems will have wide-ranging effects 
on gene expression (beyond SNCA). Unless GATA2 levels are aberrantly elevated with rotenone 
treatment – in which case silencing GATA2 expression may act to normalize GATA2 activity on 
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its target genes – the overall effects of GATA2 silencing would depend on the identity of its 
(likely numerous) target genes. Indirect down-regulation of some of these genes via GATA2 
silencing may have both deleterious and beneficial consequences for cells in the presence of 
rotenone. If this is the case, then a more targeted approach in which shRNA is directed against 
specific transcripts known to be dysregulated in PD (e.g., SNCA, TFR2, etc.) may confer 
neuroprotection against rotenone. We recently showed partial neuroprotection against rotenone 
when this approach is used to silence SNCA specifically in rat (Cannon et al., n.d.). 
A second potential reason for why GATA2 silencing failed to protect SNc dopaminergic 
neurons from rotenone toxicity relates to the treatment paradigm that we used. Using a “within” 
comparison paradigm – in which each animal serves as its own control since each hemisphere is 
exposed to a different experimental condition (AAV2.shGATA2 versus AAV2.shNeg) – has 
advantages and disadvantages. One advantage is that more powerful statistical tests can be 
applied since comparisons are paired under these conditions. But a disadvantage to this paradigm 
is that it is unclear when the largest protective effect might be detected. For example, it is 
possible in our neuroprotection study that GATA2 silencing conferred some protection against 
rotenone mid-way through treatment, but by continuing rotenone administration until the animals 
reached phenotypic endpoint, evidence of the neuroprotection was lost and the pathology of each 
hemisphere therefore looked similar. Even though the goal is robust neuroprotection, there is 
useful information to be gleaned from partial protection, which may have been observable prior 
to symptomatic endpoint. If one cohort of animals were bilaterally infused with 
AAV2.shGATA2 and another bilaterally infused with AAV2.shNeg, then it would have been 
possible to compare survival between conditions; this is not possible when using our bilateral 
infusion paradigm. 
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Although viral-mediated silencing of GATA2 in SNc does not appear to be an efficacious 
strategy for neuroprotection in PD, there are nevertheless many interesting biological questions 
regarding the role of GATA2 in SNc dopaminergic neurons in adult brain that can be addressed 
with the viral vectors we have created and validated in this dissertation project. It is likely that 
GATA2 serves as a master regulator of gene transcription in these cells, but what pathways may 
be GATA2-dependent remains unanswered. Chromatin immunoprecipitation sequencing (ChIP-
seq) on SNc dopaminergic neurons isolated and purified by FACS or laser capture 
microdissection in combination with gene expression analysis on these cells following in vivo 
transduction with AAV2.shGATA2 would provide information on GATA2 target genes. 
Knowing the target genes would allow us to infer GATA2 function in SNc and confirm GATA2 
gene targets with additional in vivo experiments. 
In summary, the experiments reported here provide the first in vivo demonstration that 
SNCA is transcriptionally regulated by GATA2 in nigrostriatal dopamine neurons. Although 
reduced levels of a-syn are protective in some circumstances (Cannon et al., n.d.), GATA2 gene 
targeting does not appear to be beneficial therapeutically – most likely because GATA2 regulates 
other genes that counterbalance the positive effects exerted by SNCA down-regulation. 
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5.0  GENERAL DISCUSSION 
5.1 SUMMARY AND SIGNIFICANCE OF FINDINGS FROM THIS DISSERTATION 
PROJECT 
The over-arching goals of this dissertation project were to test two hypotheses: 1) GATA2 
positively regulates SNCA in SNc dopaminergic neurons in vivo, and 2) silencing GATA2 in SNc 
dopaminergic neurons protects them against rotenone-induced degeneration. We first confirmed 
that GATA2 regulates SNCA in vitro, as reported by others (Scherzer et al., 2008). Next, we 
assessed whether rat would be a suitable mammalian model system for these experiments 
(Chapter 1). Based on the fact that rat SNCA contains a conserved GATA element in the same 
region as the functional element in human SNCA (Figure 3), the fact that GATA2 regulates 
SNCA in a dopaminergic rat cell line (Figure 4), and the fact that GATA2 is expressed in SNc 
dopaminergic neurons in human and in rat (Figure 6), we concluded that rat is an appropriate 
model in which to test our two hypotheses. 
Modulation of gene expression in the brain requires overcoming several anatomical and 
biochemical challenges. The brain is encased in skull and barricaded on the cellular level by the 
relatively impermeable blood-brain barrier, making therapeutic delivery difficult. Delivery of 
genes poses an additional challenge since cells are equipped with ways of degrading foreign 
nucleic acids. We chose to use viral-mediated gene delivery to brain parenchyma as a means of 
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overcoming these challenges and testing our two hypotheses. In Chapter 3, in order to create 
these viral vectors, we designed and validated in vitro siRNAs to silence rat GATA2 specifically 
(Figure 8-9), then used these sequences as a basis for creating shRNA expression cassettes, 
which were cloned into viral expression plasmids (Figure 7) and re-evaluated for their ability to 
silence rat GATA2 specifically (Figure 10). After packaging the plasmids into a viral vector 
known for its strong tropism for SNc neurons, we again validated these reagents in vitro (Figure 
11) and concluded that they are optimal for testing our two hypotheses in vivo. 
In Chapter 4, we demonstrated that delivery of the vectors to rat SNc resulted in strong, 
persistent transduction of the nigrostriatal system (Figures 12-15) but caused a modest and 
transient inflammation in the midbrain (Figures 17) that did not result in damage to the 
nigrostriatal system (Figures 18). We encountered problems in detecting GATA2 silencing at the 
protein level in vivo due to antibody specificity issues that were circumvented by using in situ 
hybridization (ISH) to detect GATA2 mRNA. We found that the viral vector expressing shRNA 
against GATA2 successfully silenced GATA2 within the SNc (Figure 22). We further found that 
silencing GATA2 in SNc neurons led to down-regulation of SNCA expression, consistent with 
GATA2 positively regulating SNCA in vivo, which confirmed our first hypothesis (Figure 22). 
We then conducted a neuroprotection study in the rotenone rat model of PD to test our second 
hypothesis, and found that GATA2 silencing was not neuroprotective against rotenone toxicity in 
the SNc, which disproved our hypothesis (Figure 23). 
Overall, this dissertation project contributes to PD research by providing the first in vivo 
demonstration of a transcription factor (GATA2) that regulates SNCA. This project also took the 
first step toward examining GATA2 function in adult rat SNc dopaminergic neurons. Based on 
our in vivo experiments in Chapter 4, we conclude that in adult SNc neurons GATA2 is neither a 
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critical selector gene for dopaminergic cell phenotype nor a critical regulator of cell survival. 
The fact that GATA2 regulates SNCA in vivo validates two approaches as useful in identifying 
transcription factors that regulate genes of interest in vivo: the innovative in silico approach used 
by Scherzer and colleagues to discover GATA transcription factors as regulators of SNCA 
(Scherzer et al., 2008), and the viral-mediated gene delivery approach we used to confirm that 
this mode of regulation occurs in vivo. Lastly, this dissertation project has demonstrated that 
GATA2 would not be an appropriate therapeutic target for neuroprotection in PD. While this 
molecular target joins the list of many others that fail as therapeutics in pre-clinical stages of 
evaluation, the process by which this was determined has provided useful insights into GATA 
transcription factor biology in the adult mammalian brain. 
5.1.1 The role of GATA2 in SNc dopaminergic neurons: an hypothesis 
To test the hypothesis that GATA2 positively regulates SNCA in vivo, we silenced GATA2 in rat 
SNc using the shRNA-expressing AAV vector we developed in Chapter 3 and assessed SNCA 
mRNA levels using ISH in Chapter 4. We found that silencing GATA2 in SNc led to a robust 
down-regulation of SNCA, indicating that GATA2 positively regulates SNCA in this brain region 
under basal conditions, and thus confirming our hypothesis (Figure 22). This is the first in vivo 
demonstration of a transcription factor that regulates SNCA. 
What purpose does positive regulation of SNCA by GATA2 serve in SNc neurons? Based 
on what is known about the role of GATA2 in other midbrain cell types, it is likely that GATA2 
functions as a master regulator of transcription in SNc dopaminergic neurons as well. GATA2 
operates in midbrain post-mitotic GABAergic neurons to select for GABAergic phenotype by 
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coordinately regulating many genes critical to GABA synthesis (Kala et al., 2009). Could 
GATA2 be involved in specifying dopaminergic phenotype in SNc dopaminergic neurons? This 
seems unlikely since TH – the enzyme that is rate-limiting in dopamine biosynthesis and thus 
critical for establishing the dopaminergic phenotype – has not been shown to be a direct target 
gene of GATA2. Also going against this hypothesized role for GATA2 is the fact that silencing 
of GATA2 per se did not result in any change in TH levels in the nigrostriatal system (Figure 18). 
If instead we examine the putative transcriptional block of genes whose expression 
correlates with that of SNCA that Scherzer and colleagues described to be regulated by GATA1 
in human blood cells, then we might entertain a different hypothesis about GATA2 function in 
SNc dopaminergic neurons (Scherzer et al., 2008). A salient feature of this list of genes is that 
three are involved in intracellular iron metabolism – ALAS2, FECH, and BLVRB (J. Chung, 
Chen, & Paw, 2012; Scherzer et al., 2008). We were intrigued by this finding since synuclein 
pathology and iron pathology are features of degenerating SNc dopaminergic neurons in PD 
(Horowitz & Greenamyre, 2010b). If we indulge in speculation, we might propose a role for 
GATA2 in stimulating iron import into mitochondria in SNc dopaminergic neurons for use in the 
synthesis of heme and iron-sulfur cluster prosthetic groups just as GATA1 is critical to these 
processes in nascent erythroblasts. 
Erythroblasts have a high demand for iron since the main function of erythrocytes – the 
fully-differentiated cell of their hematopoietic lineage – is gas exchange via hemoglobin, a multi-
subunit protein composed of globin chains that contain iron in the form of heme prosthetic 
groups. Utilizing a transcriptional program in which one transcription factor coordinately up-
regulates many enzymes and transporters involved in this process is a powerful and 
parsimonious means of rapidly meeting the high iron demands of the cell. Indeed, it has been 
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shown that GATA1 – the GATA transcription factor that is active and required during this step 
in erythroid differentiation – induces expression of ALAS2, ALAD, PBGD (involved in heme 
synthesis) (R. Ferreira, Ohneda, Yamamoto, & Philipsen, 2005; Kramer, Gunaratne, & Ferreira, 
2000); erythropoietin receptor (EpoR) (Chiba, Ikawa, & Todokoro, 1991); Abcb10 and Mfrn1 
(inner mitochondrial membrane proteins involved in iron import into the mitochondrial matrix 
for utilization in the synthesis of heme and iron-sulfur clusters) (Amigo et al., 2011; Shirihai, 
Gregory, Yu, Orkin, & Weiss, 2000); and globin chain genes (Gong, Stern, & Dean, 1991). It 
remains to be shown whether GATA1 also positively regulates FECH and BLVRB, as suggested 
by Scherzer and colleagues (Scherzer et al., 2008), but it is clear that GATA1 functions as a key 
regulator of mitochondrial iron import and utilization in erythroblasts (Figure 24a). 
How SNCA relates to this process is unclear, but there are intriguing aspects of a-syn 
biology that may explain its inclusion in this group of GATA1-regulated genes. Alpha-synuclein 
interacts with membranes and is thought to function physiologically in the recycling of vesicles 
(Chua & Tang, 2011). Although most work examining the physiological function of a-syn has 
focused on synapses, where the protein is enriched, it is possible that a-syn has much broader 
roles in vesicle recycling and perhaps endosomal trafficking. In fact, it was shown recently in 
neural cell lines and in primary neurons that a-syn participates in clathrin-mediated endocytosis 
of the TfR (Ben Gedalya et al., 2009). Participation in endosomal vesicle trafficking could 
explain its inclusion in the group of iron-related erythroid genes regulated by GATA1. The 
primary means of importing iron into erythroblasts is in a bound state to the iron carrier protein 
transferrin, which interacts with plasma membrane transferrin receptor 1 (TfR1) and proceeds 
through a well-defined process of endocytic internalization (Horowitz & Greenamyre, 2010b). 
How endocytosed iron arrives at mitochondria is a contentious issue, but is believed, in most 
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cases, to proceed by a transient fusion of endocytotic vesicles with the mitochondrial outer 
membrane (Horowitz & Greenamyre, 2010b). The surprising abundance of a-syn in human blood 
(Scherzer et al., 2008) is consistent with it playing a role in a house-keeping process like 
endocytosis. It is therefore possible that GATA1 positively regulates SNCA in parallel with these 
mitochondrial iron import and heme synthesis genes in order to facilitate further delivery of iron 
to mitochondria via endocytosis of TfR1 in association with iron-bound transferrin (Figure 24a). 
Like erythrocytes, dopaminergic neurons have a high requirement for iron since many 
cellular enzymes require iron-sulfur clusters or heme prosthetic groups for proper function and 
TH requires ferrous iron as a cofactor for its enzymatic activity (Haavik, Le Bourdelles, 
Martínez, Flatmark, & Mallet, 1991; Horowitz & Greenamyre, 2010b). It is possible that, similar 
to the role of GATA1 in erythroblasts, a similar transcriptional program driven by GATA2 is 
operational in SNc dopaminergic neurons in order to satisfy these cellular iron demands (Figure 
24b). Although some of the GATA1-regulated genes mentioned above are erythroid specific 
(e.g. ALAS2, Mfrn1) or not expressed in SNc dopaminergic neurons (e.g. TFR1), ubiquitously 
expressed homologs or distinct genes may perform the same functions (e.g. ALAS, Mfrn2) in 
SNc dopaminergic neurons. We have previously demonstrated that transferrin receptor 2 (TfR2, 
TFR2), which binds iron-loaded transferrin like TfR1 and is likewise involved in cellular iron 
import, is expressed selectively in rat SNc dopaminergic neurons, is present in mitochondrial 
membranes as well as the plasma membrane, and thus may provide an efficient mechanism for 
mitochondrial iron import in these cells (Mastroberardino et al., 2009). TFR2 contains a GATA 
element in its promoter (Kawabata et al., 2001) and Bresnick’s group has shown in 
hematopoietic cell lines that GATA2 positively and directly regulates TFR2 (Emery Bresnick, 
personal communication to JT Greenamyre). It remains to be shown whether GATA2 regulates 
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TFR2 in SNc dopaminergic neurons. Again, like erythroblasts, SNc dopaminergic neurons 
express abundant SNCA, raising the possibility that a-syn participates in clathrin-mediated 
endocytosis of TfR2 and hence has a physiological role in facilitating iron import into 
mitochondria. 
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Figure 24. Proposed model for common role of GATA transcription factors in regulation mitochondrial iron import and utilization in 
erythroblasts and SNc dopaminergic neurons. 
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 (A) Within early erythroblasts, GATA1 positively regulates genes involved in mitochondrial 
iron import (Mfrn1, Abcb10), heme synthesis (ALAS2, FECH), and hemoglobin subunits (α-
globin, β-globin). Alpha-synuclein may play a role in trafficking of endocytotic vesicles 
containing iron to mitochondria. (B) Within SNc dopaminergic neurons, GATA2 may positively 
regulate similar gene sets to carry out mitochondrial iron import and utilization, including 
alternative target genes such as Mfrn2 (as opposed to Mfrn1) , the non-erythroid isoform of 
ALAS2 (ALAS), and the SNc dopaminergic neuron-specific iron import protein, TfR2. Alpha-
synuclein may play a similar role in shuttling iron-containing vesicles to mitochondria. (BLVRB, 
which functions in catabolism of a heme degradation product may be positively regulated by 
respective GATA transcription factors in each cell type; not shown.)  
 
 
 
More experiments are needed to explore a possible common role for GATA transcription 
factors in facilitating mitochondrial iron utilization in erythroblasts and SNc dopaminergic 
neurons. Specifically, it will be important to understand whether the several aforementioned 
iron-related genes are regulated by GATA2 in SNc dopaminergic neurons. Fortunately, midbrain 
sections from the animals infused with the viral vectors can be used to answer these questions 
with the same approach that we used to demonstrate that GATA2 regulates SNCA in vivo 
(Chapter 4). Not only can we examine expression levels of the particular iron-relevant genes, we 
can also determine whether iron defects are observable in SNc dopaminergic neurons following 
GATA2 silencing by examining heme and iron levels in situ with histological stains. Such a 
finding would further support a functional role for GATA2 in SNc neuronal iron maintenance. 
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5.1.2 GATA2 silencing is not neuroprotective in the rotenone rat model of PD 
In Chapter 4, we tested the hypothesis that silencing GATA2 in SNc dopaminergic neurons 
protects these cells from rotenone-induced degeneration. The rationale for this hypothesis was 
that, since GATA2 had been shown to induce expression of SNCA and potentially genes 
involved in heme metabolism – two pathways that are dysregulated in PD – lowering GATA2 
levels (and hence lowering GATA2 activity) might attenuate downstream toxicity of these target 
genes, as well as others that may be contributing to cytotoxicity. It is unknown whether GATA2 
levels increase in PD or the rotenone rat model thereof, but GATA2 silencing could theoretically 
be neuroprotective in either case – either by lowering basal expression of GATA2 (and thus basal 
down-stream induction of target genes) or by normalizing aberrant GATA2 expression to 
physiological levels. 
We found that silencing GATA2 in SNc dopaminergic neurons did not protect them from 
rotenone toxicity, as we observed no difference in nigrostriatal integrity between the SNc that 
received the GATA2 silencing vector and the SNc that received the negative control vector 
(Figure 23). Interestingly, there was no neuroprotection despite the strong consequent down-
regulation of SNCA. When we compare this finding with the neuroprotection that was observed 
in a similar study in which we specifically silenced SNCA in rat SNc prior to rotenone treatment 
(Cannon et al., n.d.), we must conclude that either the degree of SNCA down-regulation that we 
achieved indirectly by silencing GATA2 was insufficient to prevent rotenone toxicity or that 
GATA2 regulates other genes that may have deleterious consequences for the cell when down-
regulated. In other words, the downstream beneficial effects of silencing GATA2 (e.g. SNCA 
down-regulation) may be offset by the downstream detrimental effects of suppressing expression 
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of other genes (e.g. those involved in physiological iron uptake). Examining our results from 
another perspective, we can conclude that silencing GATA2 does not render SNc dopaminergic 
neurons any more susceptible to rotenone toxicity than transduction with a control vector. This is 
noteworthy because it indicates that the gene sets that GATA2 regulates likely do not participate 
critically in cell survival. This interpretation is also consistent with our observation that silencing 
GATA2 in the absence of rotenone does not result in nigrostriatal damage (Figure 18). 
5.1.3 Future Directions 
Several experiments would aid in clarifying what role GATA2 plays in SNc. It would be 
informative to perform ChIP-seq experiments on rat ventral midbrain homogenates to determine 
which GATA element-containing genes are bound by GATA2 in vivo. If further refinement is 
needed – i.e. specific isolation of SNc dopaminergic neurons – DNA could be isolated from 
these cells using laser-capture microdissection. In parallel with this approach, it would be 
necessary to examine changes in gene expression in these cells following silencing of GATA2 in 
SNc. Combining the findings, as Bresnick’s group has done for similar experiments on erythroid 
and endothelial cells (T. Fujiwara et al., 2009; Linnemann et al., 2011), would identify a set of 
genes that are occupied and regulated by GATA2. It would be interesting to understand whether 
some of the iron-related genes that were part of the transcriptional block containing SNCA based 
on Scherzer and colleagues’ in silico data are identified (Scherzer et al., 2008). Such a finding 
would further strengthen the similarity between blood cells and neurons with respect to 
transcriptional regulation. 
  142 
In addition to looking at downstream target genes of GATA2 in rat SNc, it would also be 
interesting to understand if environmental toxins such as rotenone or MPTP alter GATA 
transcription factor activity in SNc. Since activity of the GATA2 protein could theoretically 
increase or decrease without a change in protein levels – and since there is no clear post-
translational modification that indicates active GATA2 (Bresnick et al., 2012) – we could use a 
viral gene delivery approach to transduce SNc dopaminergic neurons with a GATA factor 
activity reporter gene – e.g. a plasmid containing a GATA element in a promoter that drives 
expression of GFP when GATA factors are bound – or a negative control with a mutated GATA 
element. If GATA transcription factors are activated in SNc by a given treatment (e.g. rotenone), 
then SNc neurons would be GFP-positive. 
The viral vectors that we created in this dissertation project could also be used to study 
GATA2 biology in other brain regions that express GATA2. It would be interesting to understand 
whether the positive regulation that GATA2 exerts on SNCA is specific to SNc neurons or occurs 
in other brain regions such as the cortex. These reagents could also be used to study GATA2 
function outside of the central nervous system. GATA2 has been associated with an increased 
risk of developing early coronary artery disease and was recently shown in endothelial cells to 
regulate many genes related to inflammation, which is a central feature of atherosclerosis 
(Connelly et al., 2006; Linnemann et al., 2011). Because AAV2 has been shown to transduce 
vascular endothelial cells efficiently (Nicklin, 2001), it is possible to test the hypothesis that 
GATA2 contributes to atherosclerosis in a rat model of atherosclerosis by directing viral delivery 
to coronary arteries via intravenous infusion and then giving an atherogenic insult. We would 
expect less evidence of atherosclerosis in endothelial cells in which GATA2 has been silenced. 
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5.2 TAKING A STEP BACK: IMPORTANT UNANSWERED QUESTIONS IN PD 
RESEARCH 
5.2.1 Why do SNc dopaminergic neurons degenerate in PD? 
In his doctoral thesis published in 1919, Konstantin Tretiakoff reported that the SNc degenerates 
in PD, and while much has been learned about PD pathogenesis since then, it remains unclear 
why dopaminergic neurons in the SNc degenerate with relative selectivity. It must be 
emphasized that SNc dopaminergic neurons are not the only cells that degenerate in PD, since 
some degree of degeneration has been reported in the locus coeruleus, the raphe nucleus, dorsal 
motor nucleus of the vagus, nucleus basalis of Meynert, and some populations of 
catecholaminergic neurons in the brain stem (Lees et al., 2009). However, nigral degeneration is 
an essential neuropathological feature of the disease that accounts for the presenting motor 
symptoms, and, as such, has been the focal point for the majority of the PD research field. 
Selective vulnerability suggests that these cells have some feature(s) that render(s) them 
more susceptible to toxic insults than other cells, and indeed many such features have been 
proposed. Interestingly, none of the genes that account for monogenic forms of PD are expressed 
specifically in dopaminergic neurons. This implies that additional factors must influence 
selective vulnerability. For the most part, the features that are thought to render SNc 
dopaminergic neurons vulnerable in PD center on oxidative stress and impaired proteostasis. 
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5.2.1.1 Oxidative stress 
Dopamine, the neurotransmitter that nigrostriatal neurons use for intercellular communication, is 
prone to auto-oxidation and can thereby contribute to oxidative stress (Hastings, 2009). 
However, the ventral tegmental area (VTA), which is anatomically adjacent to the SNc, uses 
dopamine and does not degenerate in PD. Therefore, use of dopamine as a neurotransmitter is 
not a sufficient condition for selective vulnerability in PD. The fact that some non-dopaminergic 
neuronal populations also degenerate in PD means that use of dopamine as a neurotransmitter is 
not a necessary condition for selectively vulnerable cells in PD. 
SNc dopaminergic neurons project to the caudate and putamen, with axons that are highly 
ramified with many terminals (Gauthier, Parent, Levesque, & Parent, 1999). Maintenance of 
these processes represents a great energetic demand, and not surprisingly, these cells are highly 
reliant on oxidative phosphorylation as a means of generating the requisite ATP (Dickson & 
Weller, 2011). Therefore, insults to mitochondria in general and oxidative phosphorylation in 
particular may have a larger impact on these cells than on others. The rotenone rat model of PD 
illustrates this point elegantly since rotenone is a highly lipophilic complex I inhibitor that enters 
all cells of the body when administered systemically yet induces selective degeneration of SNc 
dopaminergic neurons (Betarbet et al., 2000). 
In contrast to VTA neurons, SNc dopaminergic neurons have intrinsic pacemaking 
activity which relies on a low-voltage L-type calcium channel, Ca(v)1.3 (Chan et al., 2007). The 
large calcium fluxes that these cells endure as a consequence of using these channels have been 
linked to oxidative stress via induction of calcium-responsive pro-oxidant enzymes (Guzman et 
al., 2010). Dopaminergic cells also seem to handle oxidative insults differently as compared to 
other cells. In a recent study, we examined how dopaminergic cells respond to challenge with 
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low concentrations of rotenone by examining changes in thiol oxidation over time using a novel 
redox histochemistry technique (Horowitz et al., 2011). We found a different oxidation profile in 
response to physiological oxidant exposure over time between midbrain dopaminergic neurons 
and cortical neurons. This pattern was consistent across dopaminergic neurons from multiple in 
vitro and in vivo systems, including rat primary midbrain culture, zebrafish larvae, and rat SNc 
(Horowitz et al., 2011). More studies are required in order to determine what accounts for these 
differences, but they may be due to differential utilization of various antioxidant systems, such as 
thiol buffering (e.g. glutathione) or induction of antioxidant enzymes (e.g. SOD1). Compounding 
these sources of oxidative stress is the fact that levels of antioxidants decrease with aging, 
limiting the ability of neurons to combat oxidative stress (Sohal & Orr, 2012). 
5.2.1.2 Protein dyshomeostasis 
A common feature of cells that selectively die in neurodegenerative diseases is accumulation and 
aggregation of protein (Chiti & Dobson, 2006; Saxena & Caroni, 2011). This would suggest that 
selectively vulnerable cells may have a diminished ability to properly re-fold or degrade mis-
folded proteins as compared to non-degenerating cells. Protein dyshomeostasis often occurs in 
the context of oxidative stress, again suggesting that dysfunction in multiple crucial pathways 
can tip the balance within certain cells from stress adaptation to death. Aging neurons also have 
lower levels of protein chaperones, and a consequent reduced capacity for repairing and 
degrading damaged proteins (Ebrahimi-Fakhari, Wahlster, & McLean, 2011). 
Lewy bodies (in neuronal somata) or Lewy neurites (in neuronal processes), are 
intracellular aggregates of various proteins, including misfolded and aggregation-prone proteins 
(e.g. a-syn, ubiquitinated proteins) as well as various proteins involved in protein homeostasis 
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(e.g. ubiquitin proteasome subunits, chaperones). Patients with SNCA locus multiplications 
develop a rare form of PD that is strikingly similar to sporadic PD when compared at the 
neuropathological levels – i.e. relatively selective loss of SNc dopaminergic neurons. Patients 
with triplications in the SNCA locus develop an earlier-onset, more severe form of PD than 
patients with locus duplication, suggesting that further exacerbation of protein homeostasis 
pathways results in a more severe cellular insult (Singleton et al., 2003). The subtle increase in a-
syn levels may be enough to outstrip protein refolding and degradation machinery in SNc 
dopaminergic neurons and lead to aggregation in these cells, whereas other cells can handle the 
increased toxic load of misfolded protein. 
These collective observations, as well as others, indicate that oxidative stress and 
impaired protein homeostasis are key factors in neuronal demise within the SNc. But just as very 
few cases of PD are due to one instigating pathological event (e.g. monogenic PD), SNc neuronal 
loss in PD is likely only rarely attributable to a single pathological insult sufficient to induce 
degeneration (e.g. MPTP exposure). A more likely reason for the relatively selective 
degeneration of SNc dopaminergic neurons that is observed in PD is multiple minor insults to 
pathways that render SNc dopaminergic neurons vulnerable – i.e. oxidative phosphorylation and 
protein homeostasis. These insults may be due to genetic variants or environmental exposures 
that, by themselves, impair these pathways only slightly, but collectively (and especially in the 
context of aging) are sufficient to push these cells beyond a critical threshold for survival. 
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5.3 HOW ARE WE GOING TO CURE PD? 
There are currently no disease-modifying therapies for PD. Motor symptoms can be treated 
temporarily, but neurons invariably continue to degenerate and symptoms worsen over time, 
slowly eroding the patient’s quality of life. Several challenges that beset therapeutic development 
for PD were mentioned earlier (1.1.6). Although the pharmacological outlook seems to be 
improving – with more potentially disease-modifying therapies in various stages of clinical trials 
– it is important that PD researchers collectively look beyond the pros and cons of candidate 
therapies and re-evaluate our goals and approach by focusing on a few key questions: 1) What 
are realistic goals for therapy in PD?, 2) What crucial technical or clinical advances are 
necessary to advance development and validation of disease-modifying therapeutics?, 3) What 
other changes will be important in sustaining strong translational PD research? 
5.3.1 What are realistic goals for therapy in PD? 
One of the main challenges in PD therapy is the inability to intervene early in the course of 
disease. The demise of SNc dopaminergic neurons is insidious and motor signs do not appear 
until 50-70% of these neurons have died (Lesage & Brice, 2009). Whereas most neuroprotective 
studies in animal models follow a pre-treatment paradigm – in which animals receive the 
putative neuroprotective intervention prior to toxic insult – clinicians do not have the luxury of 
treating patients before their PD has progressed considerably. Therefore, the realistic goal of PD 
therapeutic development given the currently available tools is either to protect remaining neurons 
from degenerating (neuroprotection) or to replace neurons that have already died 
  148 
(neurorestoration) (Yacoubian & Standaert, 2009). Of the main types of therapy in development 
for PD – drugs, gene therapy, and tissue transplantation – all may prove capable of staving off 
further neuron death, but only tissue transplantation may realistically achieve neurorestoration. 
Unfortunately, this approach suffered a set-back when it was demonstrated that fetal 
mesencephalic tissue grafts given to PD patients developed a-syn pathology within the fetal cells 
within 15 years of engraftment (Kordower & Brundin, 2009). These studies demonstrated that 
putting a healthy graft into an unhealthy environment may not lead to long-term 
neurorestoration, underscoring the need for a combined approach of neuroprotective and 
neurorestorative therapies. 
Any therapeutic intervention requires some degree of physiologic function in the region 
or cells that it is targeting. However, many of these systems are compromised in PD. 
Furthermore, the course of PD progression can be variable, meaning that not all patients stand to 
benefit from these interventions. Some examples may clarify this point. The fetal mesecephalic 
tissue grafts succumbed to PD pathology because they were placed in an environment marked by 
inflammation and a-syn pathology (Kordower & Brundin, 2009). It is thought that the recent 
AAV2-neurturin trial failed to show neuroprotection likely due to impaired retrograde transport 
and consequent inability to deliver the therapeutic viral plasmid from nigrostriatal terminals to 
somata (Marks et al., 2010). These are not insurmountable challenges, but they are issues that 
must be kept in mind when designing therapeutics and enrolling patients in clinical trials. 
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5.3.2 What crucial technical or clinical advances need to be made? 
Discovery of biomarkers – i.e. indicators of disease that can be measured in living individuals to 
assess risk for developing PD and/or disease progression – is the most important goal in PD 
research. Without a way to detect PD earlier (diagnostic biomarker) or track the progression of 
nigrostriatal degeneration accurately (response biomarker), evaluation of putative disease-
modifying therapeutics is stymied. A major problem in PD clinical trials is determining whether 
clinical improvement is due to relief of symptoms only or due to bona fide disease modification. 
A good diagnostic biomarker would be one that sensitively and specifically identifies individuals 
in early stages of PD, far before the emergence of symptoms (Scherzer, 2009). Such a biomarker 
might be found in bodily fluids, in brain imaging, or possibly in the astute correlation of pre-
motor symptoms. A good response biomarker would be one that accurately represents the state 
of disease over time and changes in response to improvement or decline (Scherzer, 2009). The 
discovery of biomarkers would have an enormous impact on PD clinical trials since they would 
allow for early intervention and meaningful evaluation of neuroprotection, both of which would 
improve the likelihood of successfully identifying disease-modifying therapies. 
The constellation of symptoms and course of disease progression can vary markedly 
across PD patients. In theory, it is possible that a therapeutic that is neuroprotective for one 
group of PD patients may have no effect in another group. Yet these clinically disparate PD 
cases are often combined in clinical trials, which carries the risk that any signs of therapeutic 
improvement may be masked. In the absence of a biomarker that would help categorize PD 
patients for rational inclusion or exclusion from certain clinical trials, definition of clinical sub-
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types of PD becomes paramount. Impressive efforts to do this are being undertaken, but more 
work is required (van Rooden et al., 2011). 
Before any novel therapeutic can enter clinical trials for PD, it must first be evaluated for 
efficacy in animal models of PD. None of the currently used animal models of PD accurately 
recapitulates all features of human PD, and this is not surprising given the fundamental 
differences in biology and time-scale. However, animal modeling represents a third critical 
domain requiring improvement in order to advance translational PD research. The majority of 
PD cases are thought to arise from an interaction among genes, environment, and aging, however 
nearly all PD animal models are based on a single pathogenic insult – either a mutated gene or an 
administered toxin (Horowitz & Greenamyre, 2010a). Large genome-wide association studies 
have recently uncovered many common genetic variants associated with PD, creating the 
possibility of using such variants in combination with neurotoxins in animal models (Satake et 
al., 2009; Simón-Sánchez et al., 2009). An animal model that is more representative of PD 
etiology – i.e. arising from a combination of genetic and environmental insults – may prove more 
accurate in recapitulating disease and hence more useful in the evaluation of therapeutics in pre-
clinical stages of development. 
5.3.3 How do we sustain strong translational research? 
In addition to innovation at the bench and bedside, the field of PD – and science more generally 
– needs innovation at the funding level for sustained support of translational research. Challenges 
in this domain include cuts to federal funding of research and a worrisome trend toward funding 
only “safe” projects. The two may be seen as going hand-in-hand: if federal research funding is 
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scant, then the projects with the highest likelihood of success are the ones that should receive 
support. However, this mode of operating can have a detrimental impact on innovation and 
translational progress. 
As Dr. Anne Young rightly described in her lecture, “Neurodegenerative Diseases: The 
Path to Therapy,” at the 2011 Annual Meeting of the Society for Neuroscience, the trajectory of 
progress in neurodegenerative disease research has been marked by periodic bursts of innovation 
following key discoveries rather than steadfast work on the same problems (11-15-11, 
Washington DC, USA). If we keep this view in mind, then re-prioritizing funding to be more 
supportive of riskier projects with greater potential pay-off would lead to greater progress in 
translational PD research. 
In summary, the most critical steps that must be taken to advance development of 
disease-modifying therapeutics for PD include: identification of reliable biomarkers for earlier 
diagnosis and accurate tracking of disease progression, evidence-based clinical sub-typing of PD 
patients for rational inclusion in clinical trials, and fostering of a funding environment that is 
more willing to support research that has the potential to lead to important breakthroughs. 
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APPENDIX A 
 
Figure 25. AAV2 expression plasmid used for construction of AAV2.shGATA2 and AAV2.shNeg 
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